<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95106</article-id><article-id pub-id-type="doi">10.7554/eLife.95106</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95106.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Telomere length sensitive regulation of interleukin receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mukherjee</surname><given-names>Ananda Kishore</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3082-6749</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dutta</surname><given-names>Subhajit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Singh</surname><given-names>Ankita</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shalu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Shuvra Shekhar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Antara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chatterjee</surname><given-names>Megha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Vinayagamurthy</surname><given-names>Soujanya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1465-9925</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bagri</surname><given-names>Sulochana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7407-2558</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Khanna</surname><given-names>Divya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>Meenakshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Soni</surname><given-names>Dristhi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Budharaja</surname><given-names>Anshul</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bhisade</surname><given-names>Sagar Kailasrao</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Anand</surname><given-names>Vivek</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Perwez</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Nija</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Faruq</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Ishaan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sabarinathan</surname><given-names>Radhakrishnan</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chowdhury</surname><given-names>Shantanu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7185-8408</contrib-id><email>shantanuc@igib.in</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ef28661</institution-id><institution>Integrative and Functional Biology Unit, CSIR-Institute of Genomics and Integrative Biology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053rcsq61</institution-id><institution>Academy of Scientific and Innovative Research (AcSIR)</institution></institution-wrap><addr-line><named-content content-type="city">Ghaziabad</named-content></addr-line><country>India</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049tgcd06</institution-id><institution>IIT Delhi</institution></institution-wrap><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02rb21j89</institution-id><institution>IISER Bhopal</institution></institution-wrap><addr-line><named-content content-type="city">Bhopal</named-content></addr-line><country>India</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ef28661</institution-id><institution>Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03gf8rp76</institution-id><institution>National Centre for Biological Sciences, Tata Institute of Fundamental Research</institution></institution-wrap><addr-line><named-content content-type="city">Bangalore</named-content></addr-line><country>India</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ef28661</institution-id><institution>GNR Knowledge Centre for Genome and Informatics, CSIR-Institute of Genomics and Integrative Biology</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j1xr113</institution-id><institution>Trivedi School of Biosciences, Ashoka University</institution></institution-wrap><addr-line><named-content content-type="city">Sonepat</named-content></addr-line><country>India</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dai</surname><given-names>Yunlu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r4q9n85</institution-id><institution>University of Macau</institution></institution-wrap><country>Macao</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>12</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP95106</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-12-22"><day>22</day><month>12</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-12-07"><day>07</day><month>12</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.12.07.471419"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-01"><day>01</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95106.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-07"><day>07</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95106.2"/></event></pub-history><permissions><copyright-statement>© 2024, Mukherjee, Dutta, Singh et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Mukherjee, Dutta, Singh et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95106-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95106-figures-v1.pdf"/><abstract><p>Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the <italic>IL1R1</italic> promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like <italic>IL6, IL8,</italic> and <italic>TNF</italic>. Further, <italic>IL1R1</italic> expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with <italic>IL1R1</italic> expression. The use of both IL1 Receptor antagonist (IL1RA) and <italic>IL1R1</italic> targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (&gt;90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>telomere</kwd><kwd>TRF2</kwd><kwd>telomeric repeat binding factor 2</kwd><kwd>interleukin-1 signalling</kwd><kwd>tumour macrophages</kwd><kwd>TNBC</kwd><kwd>triple-negative breast cancer</kwd><kwd>tumour immunity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009053</institution-id><institution>Wellcome Trust DBt India Alliance</institution></institution-wrap></funding-source><award-id>IA/S/18/2/504021</award-id><principal-award-recipient><name><surname>Mukherjee</surname><given-names>Ananda Kishore</given-names></name><name><surname>Singh</surname><given-names>Ankita</given-names></name><name><surname>Chatterjee</surname><given-names>Megha</given-names></name><name><surname>Verma</surname><given-names>Meenakshi</given-names></name><name><surname>Perwez</surname><given-names>Ahmad</given-names></name><name><surname>Chowdhury</surname><given-names>Shantanu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005879</institution-id><institution>National Centre for Biological Sciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>George</surname><given-names>Nija</given-names></name><name><surname>Sabarinathan</surname><given-names>Radhakrishnan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001405</institution-id><institution>Tata Institute of Fundamental Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>George</surname><given-names>Nija</given-names></name><name><surname>Sabarinathan</surname><given-names>Radhakrishnan</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001332</institution-id><institution>Council for Scientific and Industrial Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mukherjee</surname><given-names>Ananda Kishore</given-names></name><name><surname>Singh</surname><given-names>Ankita</given-names></name><name><surname>Sharma</surname><given-names>Shalu</given-names></name><name><surname>Roy</surname><given-names>Shuvra Shekhar</given-names></name><name><surname>Sengupta</surname><given-names>Antara</given-names></name><name><surname>Vinayagamurthy</surname><given-names>Soujanya</given-names></name><name><surname>Bagri</surname><given-names>Sulochana</given-names></name><name><surname>Soni</surname><given-names>Dristhi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015747</institution-id><institution>University Grants Commission</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dutta</surname><given-names>Subhajit</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001407</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Chowdhury</surname><given-names>Shantanu</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Ashoka University</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Chowdhury</surname><given-names>Shantanu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Telomere-sensitive regulation of IL1R1 by the shelterin protein TERF2 modulates tumour macrophage inflitration in triple-negative breast cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Telomeres are composed of DNA repeats (TTAGGG) and associated ‘shelterin’ proteins present at the end of each eukaryotic chromosome. Gradual shortening of telomeres and change in the telomeric structure with cell division leads to cellular senescence/death, which is crucial for tissue homeostasis (<xref ref-type="bibr" rid="bib44">Jacobs, 2013</xref>; <xref ref-type="bibr" rid="bib51">Karlseder et al., 2002</xref>; <xref ref-type="bibr" rid="bib89">Shay and Wright, 2000</xref>). During oncogenic transformation, the telomere shortening mediated cellular senescence is bypassed - resulting in uncontrolled cell proliferation and cancer progression; underlining the impact of telomeres in cancer (<xref ref-type="bibr" rid="bib11">Blackburn, 2000</xref>; <xref ref-type="bibr" rid="bib34">Hanahan and Weinberg, 2000</xref>; <xref ref-type="bibr" rid="bib59">Maciejowski and de Lange, 2017</xref>; <xref ref-type="bibr" rid="bib71">Paeschke et al., 2010</xref>; <xref ref-type="bibr" rid="bib90">Shay, 2016</xref>).</p><p>Shortening of telomeres with ageing contributes to compromised immune response (<xref ref-type="bibr" rid="bib31">Goronzy et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Hodes et al., 2002</xref>; <xref ref-type="bibr" rid="bib72">Pawelec et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Sansoni et al., 2008</xref>; <xref ref-type="bibr" rid="bib100">Weng, 2012</xref>). However, despite its relevance in cancer prognosis and intervention (<xref ref-type="bibr" rid="bib3">Artandi and DePinho, 2010</xref>; <xref ref-type="bibr" rid="bib4">Aviv et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Chew et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Balkwill and Mantovani, 2001</xref>; <xref ref-type="bibr" rid="bib33">Greider, 1998</xref>; <xref ref-type="bibr" rid="bib35">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib97">Wang et al., 2017</xref>), how telomeres influence tumour immune response is poorly understood.</p><p>Major advances show how immune cells including tumour-infiltrating-lymphocytes (TIL), tumour-associated-macrophages (TAM), natural-killer, and dendritic cells impact cancer progression (<xref ref-type="bibr" rid="bib9">Binnewies et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Gonzalez et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Jochems and Schlom, 2011</xref>; <xref ref-type="bibr" rid="bib86">Salgado and Gevaert, 2021</xref>). TAMs – typically M2 macrophage-like – predominantly promote immunosuppressive tumour microenvironment (TME) through secretion of anti-inflammatory cytokines (<xref ref-type="bibr" rid="bib13">Burkholder et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">Cassetta et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">DeNardo and Ruffell, 2019</xref>; <xref ref-type="bibr" rid="bib30">Gonzalez et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Pittet et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Jayasingam et al., 2019</xref>), implicating the role of TAMs in aggressive tumour growth (<xref ref-type="bibr" rid="bib40">Hu et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Pittet et al., 2022</xref>).</p><p>Poor prognosis in triple-negative breast cancers (TNBC; negative for estrogen receptor [ER-], progesterone receptor [PR-], and HER2 receptor [HER2-]) has been frequently associated with TAMs (<xref ref-type="bibr" rid="bib98">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib107">Yuan et al., 2014</xref>). Multiple reports show M2-like TAMs to be the most abundant monocytic immune cells in TNBC and implicate their role in invasiveness and aggressive tumour growth (<xref ref-type="bibr" rid="bib13">Burkholder et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Jeong et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Mantovani and Locati, 2013</xref>; <xref ref-type="bibr" rid="bib65">Medrek et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Oner et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib107">Yuan et al., 2014</xref>).</p><p>How the telomere length (TL) of cancer cells affects macrophage infiltration has not been studied. Seimiya. H and colleagues noted that telomere elongation led to differential expression of genes associated with innate immunity (<xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>). A published work on colorectal cancer showed the association of TL of cancer cells to immunity-related genes (<xref ref-type="bibr" rid="bib57">Lopez-Doriga et al., 2018</xref>). Another recent article showed that telomere maintenance by Telomerase (the key enzyme responsible for telomere maintenance) and ATL (alternative telomere lengthening) related mechanisms led to alteration of markers of TAM like CD163 in glioblastomas (<xref ref-type="bibr" rid="bib41">Hung et al., 2016</xref>). Taken together, these suggest the possibility of molecular links between TAM infiltration and telomeres.</p><p>TRF2 (telomeric repeat binding factor 2) is a canonical member of the telomere capping complex called ‘shelterin’ with reported extra-telomeric functions (<xref ref-type="bibr" rid="bib63">Martínez and Blasco, 2011</xref>; <xref ref-type="bibr" rid="bib95">Vinayagamurthy et al., 2020</xref>). We have reported earlier that the telomeric protein TRF2 alters gene expression in a TL-dependent fashion (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). TRF2, although primarily a telomere-binding protein, was found to associate with gene promoters throughout the genome independent of its telomere-specific functions (<xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; <xref ref-type="bibr" rid="bib92">Simonet et al., 2011</xref>; <xref ref-type="bibr" rid="bib105">Yang et al., 2011</xref>). Interestingly, TRF2 was sequestered at the telomeres and away from gene promoters in cells with relatively longer telomeres, and vice-versa in the case of cells with shorter telomeres. This led to TRF2-mediated transcriptional regulation that was dependent on telomere length (a scheme of this model shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Vinayagamurthy et al., 2023</xref>; <xref ref-type="bibr" rid="bib95">Vinayagamurthy et al., 2020</xref>).</p><p>We found that non-telomeric TRF2 transcriptionally activated interleukin-1-receptor type-1 (IL1R1) in a telomere-dependent fashion: resulting NF-kappaB (p65)-phosphorylation led to the upregulation of downstream cytokines. Telomere-sensitive IL1 signalling in TNBC was found to be correlated with enhanced TAM infiltration within the TME in tumours with relatively short telomeres. Together, these implicate telomere-sensitive immune-microenvironment in tumours.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Non-telomeric TRF2 binding at the IL1 receptor type 1 (<italic>IL1R1</italic>) promoter is telomere length dependent</title><sec id="s2-1-1"><title>Cytokine and their receptor-related genes are telomere-sensitive in cancer cells</title><p>We performed an RNA-seq experiment using our previously reported fibrosarcoma model of telomere elongation (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). The transcriptomic profile of HT1080 cells (short telomere cells) was compared with HT1080-LT (long telomere cells). The difference in telomere length between the cells was confirmed using flow cytometry (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). The HT1080-LT cells had constitutively higher expression of <italic>TERT</italic> and <italic>TERC</italic> as previously described (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). The telomere length of the cells was further confirmed using in situ hybridization of telomeric probes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Upon analyzing the RNA-seq data, we observed that several cytokine-related genes like <italic>IL1B</italic>, <italic>IL1R1</italic>, <italic>TNF</italic>, <italic>IL15,</italic> and <italic>IL37</italic> had higher expression in HT1080 (short telomere) cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). We looked at the enriched pathways (KEGG) in genes that were upregulated (twofold or higher expression) and down-regulated (0.5-fold or lower expression) in HT1080 cells (short telomere) compared to HT1080-LT (long telomere) cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E and F</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). It was observed that ‘cytokine- cytokine receptor interaction’ was one of the top 5 most enriched pathways for the upregulated genes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). While telomere elongation affected multiple pathways, we were most interested in cytokine-related genes that were differentially expressed due to the now well-established focus on the telomere-immunity axis (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Goronzy et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>; <xref ref-type="bibr" rid="bib100">Weng, 2012</xref>; <xref ref-type="bibr" rid="bib106">Ye et al., 2014</xref>). We revisited our published ChIP-seq data in HT1080 fibrosarcoma cells (<xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>) and found multiple cytokine-related gene promoters where TRF2 had peaks within 1000 bp from the transcriptional start site (TSS; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We validated these sites by ChIP-qPCR in HT1080 fibrosarcoma cells and found that the <italic>IL1R1</italic> promoter had the most prominent TRF2 enrichment among the sites (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2G</xref>). We further performed ChIP-qPCR spanning +200 to –1000 bp of the <italic>IL1R1</italic> TSS to confirm promoter TRF2 binding across multiple cell lines- HT1080 fibrosarcoma, MDAMB231 breast cancer, HEK293T immortalised kidney and MRC5 fibroblast cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2H</xref>).</p></sec><sec id="s2-1-2"><title>Telomere-dependent IL1R1 regulation in ex vivo fibrosarcoma cells</title><p>Next, we tested the telomere dependence of TRF2 binding based on TL-sensitive non-telomeric TRF2 binding observed earlier (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). TRF2-ChIP in ex vivo cultured HT1080-LT/HT1080 cells showed that TRF2 occupancy at the <italic>IL1R1</italic> promoter was significantly reduced in cells with long telomeres relative to short telomere cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). <italic>IL1R1</italic> mRNA expression was significantly lower in HT1080-LT relative to HT1080 cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) conforming to the RNA-seq data described earlier (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). We found that the IL1R1 protein was also lower in HT1080-LT cells (flow cytometry; <xref ref-type="fig" rid="fig1">Figure 1C</xref>; western blot in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2I</xref>). Consistent with this, expression of IL1R1 at the cell surface was significantly lower in HT1080-LT compared to HT1080 cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Expression of IL1R1 is regulated by telomere length-dependent enrichment of non-telomeric TRF2 on the gene promoter.</title><p>(<bold>A</bold>) Occupancy of TRF2 was checked by ChIP-qPCR on the <italic>IL1R1</italic> promoter spanning +200 to –1000 bp of TSS was reduced ex vivo HT1080 cells with long telomeres (HL1080-LT) relative to ones with short telomeres (HT1080) cells (N=3 in each case); IL1R1-3’UTR or a region 20 kb upstream were used as negative controls for TRF2 binding. Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>B</bold>) mRNA expression of <italic>IL1R1</italic> in ex vivo HT1080 or HT1080-LT cells; <italic>GAPDH</italic> was used for normalisation [N=3]. Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) IL1R1 protein expression was checked by immuno-flow cytometry in HT1080 or HT1080-LT cells in three independent replicates; Mean IL1R1 expression has been plotted along the X-axis in log scale (right panel) [N=3]. Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) IL1R1 levels by immunofluorescence microscopy in HT1080 or HT1080-LT cells; cells were stained with DAPI for marking the cell nucleus; IL1R1 levels from 25 individual cells shown in graph (right panel). [N=25] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) Telomere length of the xenograft tumours made in NOD SCID mice using HT1080 cells with long telomeres (HL1080-LT) and short telomeres (HT1080) was checked by flow-cytometry and was higher in HT1080-LT xenograft tumours. Following this, IL1R1 expression was checked by flow cytometry for these samples. Mean Telomeric signal and Mean IL1R1 expression has been plotted respectively (panels below) [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>F</bold>) Occupancy of TRF2 by ChIP-qPCR at the <italic>IL1R1</italic> promoter spanning +200 to –1000 bp of TSS was reduced in xenograft tumours made from HT1080 cells with long telomeres (HL1080-LT) relative to ones with short telomeres (HT1080) cells (N=3 in each case; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls for TRF2 binding). [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>G</bold>) mRNA expression of <italic>IL1R1</italic> in xenograft tumours (HT1080 or HT1080-LT cells); <italic>18</italic> S was used for normalisation. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>H</bold>) Telomere length by flow-cytometry of telomeric signal in HT1080 cells (hTERT-inducible stable line) following 0, 1, 6, 12, or 20 days of hTERT induction; HT1080-LT shown as positive control for enhanced telomere length; mean telomeric signal (FITC) plotted bar graph (left). [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>I</bold>) TRF2 occupancy ChIP-qPCR on the <italic>IL1R1</italic> promoter spanning +200 to –1000 bp of TSS in HT1080 cells following 0, 1, 6, or 12 days of hTERT induction in ex vivo culture; primers and normalisation as in <xref ref-type="fig" rid="fig2">Figure 2A</xref>; IL1R1-3’UTR or a region 20 kb upstream used as negative controls. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>J</bold>) <italic>IL1R1</italic> mRNA expression (normalised to <italic>GAPDH</italic>) in HT1080 cells following 0, 1, 6, or 12 days of hTERT induction in ex vivo culture. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>K</bold>) TRF2 occupancy by ChIP-qPCR on the <italic>IL1R1</italic> promoter in MDAMB23 or MDAMD231-LT cells using primers and normalisation described earlier. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>L</bold>) Expression for <italic>IL1R1</italic> in MDAMB231 cells or MDAMD231-LT cells; <italic>GAPDH</italic> was used for normalisation. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig1">Figure 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Graphical representation of the Telomere Sequestration Partitioning (TSP) model.</title><p>The binding of TRF2 outside of telomeric regions (non-telomeric) is dependent on telomere length. When telomeres shorten, the presence of TRF2 at telomeres diminishes, resulting in increased TRF2 binding at non-telomeric sites. This shift in TRF2 distribution triggers epigenetic modifications at promoters showing telomere-dependent gene regulation. Described in <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Expression of IL1R1 is regulated by telomere length-dependent enrichment of non-telomeric TRF2 on the gene promoter (continued).</title><p>(<bold>A</bold>) Telomer length (TL) by flow-cytometry analysis of telomeric signal (FITC labelled PNA probe) showing increase in TL in HT1080-LT cells relative to HT1080 cells; plotted along x-axis in log scale. (<bold>B</bold>) <italic>TERT</italic> and <italic>TERC</italic> expression as expected was enhanced in HT1080-LT relative to HT1080 cells (normalised to GAPDH). [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) Immuno-histochemical (IHC) staining of previously reported and well-characterised cells with short/long telomeres (fibrosarcoma HT1080 or the long-telomere version HT1080-LT cells in cell-isogenic background) hybridised with telomere-specific FITC-labelled PNA probe, counterstained with DAPI (left panel); telomeric signal was enhanced in HT1080-LT cells (quantified in right panel). [N=15] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) Volcano plot of expressed genes in RNA-seq in HT1080 or HT1080-LT cells; x-axis has log-2 fold change for genes and the y-axis represents adjusted p values in log-10 scale. Key inflammation-related genes that have been marked in figure – most differentially expressed genes like <italic>IL1R1</italic>,<italic>IL1B</italic> and <italic>IL10</italic> were found to have higher expression in HT1080 cells compared to HT1080-LT cells. TERT which (as expected) is significantly lower in HT1080 cells compared to HT1080-LT cells have been also marked. Upregulated and downregulated genes listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>E</bold>) Gene Ontology (KEGG) for upregulated genes in HT1080 cells over HT1080-LT cells. (<bold>F</bold>) Gene Ontology (KEGG) for down-regulated genes in HT1080 cells over HT1080-LT cells. (<bold>G</bold>) Occupancy of TRF2 by ChIP-qPCR checked in HT1080 cells for cytokine-related genes. Enrichment was plotted relative to mock IgG (post normalisation to 1% input) [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>H</bold>) TRF2 occupancy on the <italic>IL1R1</italic> promoter in HT1080, MDAMB231, HEK293T or MRC5 cells by chromatin-immunoprecipitation (ChIP) followed by qPCR. Primers spanning +200 to –1000 bp of TSS used for TRF2 enrichment on the gene promoter; 3’UTR and –20 Kb upstream of TSS used as negative control for TRF2 binding; fold-change of occupancy was calculated over mock IgG after normalizing signal to 1% input. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>I</bold>) IL1R1 protein levels in HT1080 and HT1080-LT cells by western blot; GAPDH was used as loading control. (<bold>J</bold>) mRNA expression of <italic>hTERT</italic> and <italic>TERC</italic> (normalised to 18 S) in xenograft tumours in NOD-SCID mice injected with HT1080 or HT1080-LT cells. <italic>18</italic> S has been used as a normalizing control. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>K</bold>) <italic>hTERT</italic> mRNA expression in hTERT-inducible HT1080 cells on treatment with different concentrations of doxycycline [N=2] (left panel) and at different days following induction [N=3] (right panel). <italic>GAPDH</italic> was used for normalisation. Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>L</bold>) Relative telomere length by qRT-PCR in MDAMB231 or MDAMD231-LT (long telomere) cells in three independent experiments. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2I</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig1-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata3"><label>Figure 1—figure supplement 2—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig1-figsupp2-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig1-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-1-3"><title>Telomere-dependent IL1R1 regulation in xenograft tumours</title><p>We generated xenograft tumours using HT1080 and HT1080-LT cells in NOD-SCID mice (see methods for details). We confirmed that there was higher expression of <italic>TERT</italic> and <italic>TERC</italic> in the HT1080-LT xenograft tumours (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2J</xref>). We found that the xenograft tumours from HT1080-LT cells had higher mean telomere length than those from HT1080 cells and had lower IL1R1 expression at the protein level (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). It was observed that TRF2 occupancy (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), as well as <italic>IL1R1</italic> mRNA (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) expression, was lower in HT1080-LT-derived xenograft tumours.</p></sec></sec><sec id="s2-2"><title>TERT-inducible model of telomere elongation in fibrosarcoma cells</title><p>Telomere-dependent TRF2 binding at the <italic>IL1R1</italic> promoter was further checked using <italic>hTERT</italic>-inducible HT1080 cells that gradually increased telomeres by ~50% over 12 days following hTERT induction (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2K</xref>): gradual reduction of <italic>IL1R1</italic> promoter TRF2 binding (<xref ref-type="fig" rid="fig1">Figure 1I</xref>) and <italic>IL1R1</italic> expression (<xref ref-type="fig" rid="fig1">Figure 1J</xref>) with telomere elongation over the 12 days was notably consistent with observations made using HT1080/HT1080-LT cells (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>).</p><sec id="s2-2-1"><title>Telomere elongation model in MDAMB231 breast cancer cell line</title><p>An alternative telomere elongation model was made from TNBC MDAMB-231 cells using G-rich-telomere-repeat (GTR) oligonucleotides as reported earlier (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Wright et al., 1996</xref>). In the resulting MDAMB-231-LT cells with ~1.8- to twofold increase in TL (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2L</xref>), <italic>IL1R1</italic> promoter TRF2 occupancy and <italic>IL1R1</italic> expression were significantly lower (<xref ref-type="fig" rid="fig1">Figure 1K and L</xref>). The results collectively suggest that TRF2 occupancy at the <italic>IL1R1</italic> promoter and the expression of the gene is telomere length dependent.</p></sec></sec><sec id="s2-3"><title>TRF2 transcriptionally activates <italic>IL1R1</italic></title><p>We, next, investigated the role of TRF2 in the regulation of <italic>IL1R1</italic>.TRF2 over-expression (Flag-TRF2) showed an increase in <italic>IL1R1</italic> mRNA expression and protein, and TRF2 silencing reduced <italic>IL1R1</italic> in HT1080 cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) indicating that TRF2 activated <italic>IL1R1</italic> expression. Flag-tagged TRF2-full-length, or a truncated version of flag-tagged TRF2 protein without the necessary domains for DNA binding (N-terminal Basic-domain [TRF2-delB] or C terminal MYB-domain TRF2-delM), showed that both TRF2 occupancy and <italic>IL1R1</italic> promoter activity was compromised in case of the mutants; indicating TRF2 DNA binding as necessary for <italic>IL1R1</italic> activation (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). We developed a doxycycline-inducible TRF2 model using HT1080 cells. Upon induction of TRF2, IL1R1 expression was also enhanced (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). We checked and found that IL1R1 expression of the cell surface was also significantly higher in cells with higher TRF2 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Further, TRF2-dependent activation of <italic>IL1R1</italic> was clear in MDAMB-231 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), normal MRC5 fibroblasts and HEK293T cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). HT1080 cells with doxycycline-inducible-TRF2 were used to make tumour xenografts in NOD-SCID mice. TRF2-induced tumours had enhanced IL1R1 relative to the xenograft tumours where TRF2 was not induced (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TRF2 is a transcriptional activator of IL1R1.</title><p>(<bold>A</bold>) <italic>IL1R1</italic> expression by qRT PCR following expression of TRF2-flag or TRF2 silencing (48 hr of transient transfection); <italic>GAPDH</italic> was used for normalisation. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>B–C</bold>) TRF2 ChIP-qPCR spanning +200 to –1000 bp of <italic>IL1R1</italic> TSS for TRF2 occupancy (<bold>B</bold>) and promoter activity (luciferase reporter including –1500 bp TSS); (<bold>C</bold>) following expression of flag-tag TRF2 full-length, or the mutants TRF2-delB or TRF2-delM; anti-flag antibody used for ChIP; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) TRF2 and IL1R1 levels by western blots following TRF2 induction with 2 or 4 µg/ml doxycycline (Dox) in HT1080 cells (stably transformed for Dox-inducible TRF2); GAPDH as loading. (<bold>E</bold>) TRF2 and IL1R1 expression in control or TRF2-induced HT1080 cells by flow-cytometry; TRF2/IL1R1 in x-axis in log scale for 20,000 cells. (<bold>F</bold>) IL1R1 levels in control or TRF2-induced HT1080 cells. CD44 used for cell-surface marker and nuclei were stained with DAPI; 25 cells in each condition were scored and plotted in the summary graph. [N=25] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>G</bold>) TRF2 (left panel), IL1R1 (right panel) levels from xenograft tumours in NOD-SCID mice (control or doxycycline-induced TRF2 in HT1080 cells; N=6 mice in each group) by immuno-flow cytometry; mean fluorescence signal from individual tumours in control or TRF2-induced tumours plotted in adjacent graphs. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig2">Figure 2</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig2">Figure 2D</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Original image files for western blot or <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig2-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>TRF2 is a transcriptional activator of IL1R1 (continued).</title><p>(<bold>A</bold>) IL1R1 protein levels on TRF2-flag induction (left) or TRF2 silencing (right) in HT1080 cells following 48 hr of transfection. (<bold>B</bold>) IL1R1 mRNA expression in MDAMB231 cells following expression of TRF2 cDNA or TRF2 silencing for 48 hr; GAPDH used as normalizing control (left). [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). IL1R1 protein levels in MDAMB231 cells following TRF2 induction for 48 hr by western blot (centre) and immuno-flow cytometry (right). (<bold>C</bold>) <italic>IL1R1</italic> mRNA expression in HEK293T and MRC5 cells following transfection of TRF2-cDNA for 48 hr; <italic>GAPDH</italic> was used as normalizing control. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig2-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>G-quadruplex DNA secondary structure is necessary for TRF2 binding to the <italic>IL1R1</italic> promoter</title><p>We reported TRF2 binding to G-quadruplex (G4) DNA secondary structures within promoters throughout the genome <xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; further, the role of G4s in epigenetic regulation was noted (<xref ref-type="bibr" rid="bib68">Mukherjee et al., 2019b</xref>). Here, we found two G4s within the <italic>IL1R1</italic> promoter TRF2-binding site (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). We confirmed that the DNA sequences formed G4 structures in solution and specific base substitutions disrupted the structure formation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>); both G4 forming motif sequences showed the characteristic Circular Dichroism signatures for ‘parallel’ G-quadruplex structures which were largely abrogated when the sequences were mutated (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). BG4 antibody [against G4s (<xref ref-type="bibr" rid="bib8">Biffi et al., 2013</xref>)] ChIP was enriched ~200 bp upstream on the <italic>IL1R1</italic> promoter in HT1080 cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>); TRF2-dependent <italic>IL1R1</italic> promoter activity was significantly compromised on introducing G4-deforming G˃T substitutions on both the G4 motifs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), while the effect of the mutation was more for G4 motif B. In the presence of the intracellular G4-binding ligand 360 A (<xref ref-type="bibr" rid="bib32">Granotier et al., 2005</xref>), the TRF2 occupancy in HT1080 cells was found to be significantly reduced at the <italic>IL1R1</italic> promoter consistent with results from other TRF2 binding sites (<xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Upon treatment of HT1080 cells with 360 A, TRF2-induced IL1R1 promoter activity, and expression/protein were significantly reduced (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Using CRISPR, we artificially inserted an <italic>IL1R1</italic> luciferase-reporter-cassette (–1500 bp) at the CCR5 safe-harbour locus in HEK293T cells; TRF2-dependent promoter activity from the inserted <italic>IL1R1</italic> promoter-reporter and TRF2 binding was reduced when the G4 motif B was mutated supporting earlier results (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). Furthermore, CRISPR-mediated G&gt;T editing in the G4 motif (motif B) within the endogenous <italic>IL1R1</italic> promoter resulted in a reduction of TRF2 binding and <italic>IL1R1</italic> expression (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>DNA secondary structure G-quadruplexes are important for TRF2 binding to IL1R1 promoter.</title><p>(<bold>A</bold>) Schematic depicting G4 motifs (<bold>A, B</bold>) and their respective positions on the <italic>IL1R1</italic> promoter; sequence scheme depicting generic G4 motifs; (<bold>B</bold>) Circular dichroism profile (220–310 nm wavelength) of oligonucleotides (5 µM) with sequence of the G4 motifs A or B (or respective mutants with base substitutions) in solution. (<bold>C</bold>) ChIP-qPCR following BG4 ChIP at the IL1R1 promoter (fold enrichment over mock) overlaid with TRF2 occupancy (fold enrichment over IgG) in HT1080 cells. [N=3] Statistical significance was calculated using Šídák’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) IL1R1 promoter activity in HT1080 cells from luciferase-reporter without or with G4-deforming substitutions against G4 motif A (IL1R1G4-MUT-A) or G4 motif B (IL1R1-G4 MUT-B) in presence or absence of TRF2 induction; G4 motifs A and B as shown in schematic; specific base substitutions have been indicated in blue font. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) <italic>IL1R1</italic> promoter activity, mRNA and protein levels in presence/absence of the G4 binding ligand 360 A with or without TRF2 induction. For Left and centre panels- [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>F</bold>) IL1R1 promoter-firefly luciferase reporter cassette, with or without substitutions deforming the G4 motif B, was artificially inserted at the CCR5 locus using CRISPR-cas9 gene editing in HEK293T cells (scheme in left panel). Promoter activity from (right panel). [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>G</bold>) TRF2 occupancy by ChIP-qPCR (right panel) at the artificially inserted IL1R1 promoter without or with G4-deforming substitutions (IL1R1G4 MUT-B);ChIP-qPCR primers designed specific to the inserted promoter using the homology arms(see Materials and methods). [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig3">Figure 3</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig3">Figure 3E</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig3">Figure 3E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig3-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>DNA secondary structure G-quadruplexes are important for TRF2 binding to IL1R1 promoter (continued).</title><p>(<bold>A</bold>) TRF2 ChIP-seq peak with sequence of the G4 motifs (<bold>A, B</bold>) and their respective positions on the <italic>IL1R1</italic> promoter. (<bold>B</bold>) Occupancy of TRF2 by ChIP-qPCR at the <italic>IL1R1</italic> promoter at the region of 0–200 bp of TSS in presence of ligand 360 A in three independent experiments in HT1080 cells. The dosage of 360 A used has been previous standardised (<xref ref-type="bibr" rid="bib68">Mukherjee et al., 2019b</xref>) [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C, D</bold>) Base substitutions for the G4 motif B in the IL1R1 promoter (as shown in <xref ref-type="fig" rid="fig3">Figure 3D</xref>) were introduced using CRSIPR in HEK293T cells. TRF2 ChIP-qPCR spanning the IL1R1 promoter (left) and <italic>IL1R1</italic> mRNA expression (right) in HEK293T cells with or without the G4-disrupting substitution in two replicates. [N=2]. Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>TRF2-dependent recruitment of histone acetyltransferase p300 induces H3K27ac modification at the <italic>IL1R1</italic> promoter</title><p>We had previously reported that TRF2 occupancy alters the local epigenetics at gene promoters (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). Here, we sought to understand if TRF2 occupancy brought about any epigenetic alteration at the <italic>IL1R1</italic> promoter. Screening of activation (H3K4me3 and H3K27ac) and repressive (H3K27me3, H3K9me3) histone marks at the <italic>IL1R1</italic> promoter following TRF2 induction, showed enhanced H3K27acetylation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). In both HT1080 and MDAMB-231 cells, <italic>IL1R1</italic> promoter H3K27 acetylation increased/reduced on TRF2 induction/silencing respectively (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We sought to find a potential histone acetyltransferase (HAT) and noted canonical HATs p300/CBP (<xref ref-type="bibr" rid="bib85">Roth et al., 2001</xref>) at the <italic>IL1R1</italic> promoter in multiple cell lines in ENCODE (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). ChIP-qPCR confirmed p300 occupancy within upstream 200–400 bp promoter of <italic>IL1R1</italic> in TRF2-up conditions, which reduced significantly on TRF2 downregulation, in HT1080 and MDAMB-231 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Furthermore, occupancy of acetylated-p300/CBP (activated HAT) was enriched at the <italic>IL1R1</italic> promoter on TRF2-induction in HT1080 cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Together these showed TRF2-mediated recruitment and acetylation of p300/CBP, resulting in H3K27 acetylation at the <italic>IL1R1</italic> promoter. <italic>IL1R1</italic> promoter occupancy of p300, CBP, ac-p300/CBP and H3K27ac was relatively low in HT1080-LT compared to HT1080 cells with shorter telomeres (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) consistent with lower TRF2 occupancy at the <italic>IL1R1</italic> promoter in LT cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TRF2 recruits the histone acetyl transferase p300 to the <italic>IL1R1</italic> promoter.</title><p>(<bold>A</bold>) H3K27ac occupancy at the <italic>IL1R1</italic> promoter spanning +200 to –1000 bp of TSS by ChIP-qPCR in HT1080 (left panel) and MDAMB231 cells (right panel) in control (uninduced), TRF2-induced (up) or TRF2-down conditions; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>B</bold>) p300 occupancy on the <italic>IL1R1</italic> promoter in HT1080 (left panel) and MDAMB231 cells (right panel) in control (uninduced), TRF2-induced or TRF2-down conditions; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) CBP (left panel) and ac-p300/CBP (right panel) occupancy on the <italic>IL1R1</italic> promoter in HT1080 cells in control (uninduced) or TRF2-induced conditions; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. [N=3] Statistical significance was calculated using Šídák’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) p300, CBP, acp300/CBP and H3K27Ac occupancy on the <italic>IL1R1</italic> promoter in HT1080 and HT1080-LT cells; IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. [N=3] Statistical significance was calculated using Šídák’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). All protein ChIP, other than histones, were normalised to 1% input and fold-change have been calculated over respective IgG. Histone ChIP were normalised to 1% Input and fold change over total H3 have been calculated for individual samples (Further details in the Materials and methods section). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig4">Figure 4</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>TRF2 recruits the histone acetyl transferase p300 to the IL1R1 promoter (continued).</title><p>(<bold>A</bold>) Enrichment of histone marks H3K27ac, H3K4me3, H3K27me3, H3K9me3 (normalised to total H3) by ChIP-qPCR on the <italic>IL1R1</italic> promoter in HT1080 cells in TRF2-up (induced) condition or un-induced corresponding control cells. [N=3] Statistical significance was calculated using Šídák’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>B</bold>) Transcription factors/histone remodelers on the IL1R1 proximal promoter (–750 bp) across seven cell lines curated from ENCODE was plotted using UCSC genome browser hg19 human genome assembly. P300 enrichment marked in red box. (<bold>C</bold>) Immunoprecipitation using TRF2 antibody probed for p300, acp300/CBP, TRF2 or TRF1 (positive control) in input, TRF2 IP fraction or mock IP fraction in HT1080 cells. (<bold>D</bold>) Histone acetyl transferase (HAT) assay using purified histone H3/H4 and full-length p300 as substrate in presence/absence of recombinant TRF2; BSA (bovine serum albumin) was used as a non-specific mock protein. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig4-figsupp1-v1.tif"/></fig></fig-group><p>A recent work showed that TRF2 can physically interact with p300 and p300 acetylates TRF2 at specific lysine residues (<xref ref-type="bibr" rid="bib36">Her and Chung, 2013</xref>). We found that TRF2 directly interacted with p300, evident from co-immunoprecipitation using lysate from HT1080 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). To ascertain direct TRF2-p300 interaction and consequent H3K27 acetylation, we did histone-acetyl-transfer assays using purified p300, histone H3, and acetyl-CoA (substrate for the acetyl group) with or without recombinant TRF2. Transfer of the acetyl group to histone H3 was significantly enhanced in the presence of both TRF2 and p300, relative to p300 only; and TRF2 co-incubated with p300 without H3 gave marginal HAT activity (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). These together demonstrate a direct function of TRF2 in recruitment and HAT activity of p300 in H3K27 acetylation at the <italic>IL1R1</italic> promoter.</p></sec><sec id="s2-6"><title>Acetylation of TRF2 at Lysine residue 293 is necessary for p300 recruitment on the <italic>IL1R1</italic> promoter</title><p>We sought to understand if the acetylation of TRF2 was important for p300-TRF2 complex recruitment to the <italic>IL1R1</italic> promoter. We found that several residues on TRF2 have been reported to be acetylated /deacetylated (<xref ref-type="bibr" rid="bib81">Rizzo et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Her and Chung, 2013</xref>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). To test the direct function of TRF2 acetylation in p300 recruitment, Flag-TRF2 mutants [K176R, K179R, K190R, and K293R (<xref ref-type="bibr" rid="bib81">Rizzo et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Her and Chung, 2013</xref>)] were screened (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) for effect on <italic>IL1R1</italic> expression. TRF2-K293R gave notably compromised activation of <italic>IL1R1</italic> at mRNA and protein levels (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). The binding of flag-TRF2-293R at the <italic>IL1R1</italic> promoter was similar to TRF2-WT (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) suggesting that the loss in <italic>IL1R1</italic> activation was not due to lower promoter binding by TRF2-293R. However, TRF2-293R significantly reduced p300 and ac-p300/CBP recruitment on the <italic>IL1R1</italic> promoter relative to TRF2-wildtype (WT) induction (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). TRF2 293R also showed lower physical interaction with p300 in an immunoprecipitation experiment in comparison to TRF2 WT (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). The TRF2 mutant K293R, devoid of H3K27 acetylation activity, gave a loss of function (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). Therefore, TRF2-K293R was fused to dead-Cas9 (dCas9-TRF2-K293R), and dCas9-TRF2 was used as control. On using sgRNA against the <italic>IL1R1</italic> promoter, we found significant activation or downregulation of <italic>IL1R1</italic> in the case of dCas9-TRF2 or dCas9-TRF2-K293R, respectively, in HT1080 and MDAMB231 cells. In contrast, other TRF2-target genes (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>) remained unaffected indicating single-gene specificity (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). We further checked the role of the TRF2 mutant K293R on other targets of TRF2 that we had previously validated (<xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). While the TRF2 mutant K293R did not show much effect on genes wherein TRF2 acted as a transcriptional repressor, the effect on the candidate ‘activation’ targets of TRF2 was not uniform as well. The Lysine 293 in TRF2 seems to be important for activation but not repression. However, while the mutant K293R diminished TRF2-mediated activation of <italic>IL1R1</italic> and <italic>PDGFR-B</italic>, it did not affect <italic>WRNIP1</italic>. This suggests that the TRF2 PTMs might have context-dependence at specific loci in the genome.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Acetylation of TRF2 at Lysine residue 293 is necessary for p300 recruitment on the <italic>IL1R1</italic> promoter.</title><p>(<bold>A</bold>) Schematic showing positions (amino acid residues) where acetylation and deacetylation of TRF2 have been reported. (<bold>B</bold>) IL1R1 mRNA expression post 48 hr of transient over-expression of various TRF2 acetylation mutants. <italic>GAPDH</italic> was used for normalisation. [N=3] Statistical significance was calculated using Dunnett’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) IL1R1 protein level following post 48 hr of transient over-expression of various TRF2 acetylation mutants; GAPDH used as loading control. (<bold>D</bold>) Immunofluorescence for IL1R1 in HT1080 cells without (control) or with induction of flag-tag TRF2 WT or mutant TRF2-293R; quantification from 29 cells in each case shown in graph. [N=29] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) Occupancy of flag-tag TRF2-WT or TRF2-293R on the IL1R1 promoter by ChIP-qPCR in HT1080 cells (left panel); IL1R1-3’UTR or a region 20 kb upstream were used as negative controls. Occupancy by ChIP-qPCR of p300 (middle panel) and acp300/CBP (right panel) without (control) or with induction of TRF2-WT and TRF2-293R. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>F</bold>) TRF2-wild type (WT) and TRF2-2293R mutant proteins fused with dCAS9 expressed and targeted to the IL1R1 promoter using <italic>IL1R1</italic>-specific gRNA in HT1080 and MDAMB231 cells. Following this, expression of <italic>IL1R1</italic> or other TRF2 target genes (non-specific with respect to the IL1R1-gRNA) in HT1080 (left) or MDMB231 cells (right). [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig5">Figure 5</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig5">Figure 5C</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig5-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Acetylation of TRF2 at Lysine residue 293 is necessary for p300 recruitment on the IL1R1 promoter (continued).</title><p>(<bold>A</bold>) TRF2-WT Flag or TRF2 K293R-Flag was stably over expressed in HT1080 cells and immunoprecipitation was performed using Anti-Flag antibody or Mock IgG. Enrichment for p300 in IP faction was tested for TRF2-WT (left) and TRF2 K293R(right). (<bold>B</bold>) Previously reported TRF2 target genes (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>) were checked following transient over-expression of TRF2 WT and TRF2 K293R in HT1080 cells. While K293R did not affect TRF2 mediated repression, it affected TRF2 activated genes PDGFR-B and IL1R1 but not WRNIP1. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig5-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Cancer cells with higher TRF2 are sensitive to IL1-mediated NF-kappaB (p65) activation</title><p>Primarily ligands IL1A/B via receptors IL1R1/R2 activate IL1 signalling through NF-KappaB (p65/RELA)-Ser536 phosphorylation (<xref ref-type="bibr" rid="bib99">Weber et al., 2010</xref>). This induces <italic>IL1B</italic> and other inflammatory genes including <italic>IL6, IL8,</italic> and <italic>TNF</italic>. Here, we checked NF-kappaB-Ser536 phosphorylation following stimulation with IL1B in the presence/absence of TRF2 in HT1080 and MDAMB-231 cells. TRF2-induction gave relatively enhanced NF-kappaB-Ser536 phosphorylation that sustained for a longer duration compared to uninduced controls in both cell types; total NF-kappaB levels remained unaltered (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Accordingly, on stimulation with either IL1A or IL1B in a TRF2-silenced condition, expression of the NF-kappaB targets <italic>IL6, IL8,</italic> and <italic>TNF</italic> were reduced (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Further, the ligand TNFα was reported to induce NF-kappaB in an IL1-independent fashion (<xref ref-type="bibr" rid="bib55">Liu et al., 2017</xref>) suggesting this pathway would be unaffected by the presence/absence of TRF2. Indeed, the expression of NF-kappaB targets (<italic>IL6, IL8,</italic> and <italic>TNF</italic>) remained unaffected upon stimulation by TNFαin the absence of TRF2, supporting the role of TRF2 in IL1 signalling specifically (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Additionally, TRF2 induction enhanced the expression of <italic>IL6</italic>, <italic>IL8,</italic> and <italic>TNF</italic>, which was rescued in the presence of the receptor antagonist IL1RA, further confirming the specific role of TRF2-IL1R1 in NF-kappaB activation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). When tested in NOD SCID mouse xenograft tumour samples, we observed that the ratio of phosphor-NF-kappaB to total NF-kappaB B was significantly higher in TRF2-induced tumours (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TRF2-dependent IL1 pathway activates NFkappa B (p65) in cancer cells.</title><p>(<bold>A, B</bold>) NFKappaB activation in presence of IL1B (10 ng/ml) in HT1080 (<bold>A</bold>) or MDAMB231 (<bold>B</bold>) cells with or without TRF2 induction; activation signalling was confirmed through NFKappaB-Ser536 phosphorylation (normalised to total NFKappaB); ratio of Ser566-p/total NFKappaB plotted for respective blots from three independent replicates (right panels). [N=2]. (<bold>C</bold>) Expression of NFKappaB targets <italic>IL6, IL8</italic> or <italic>TNF</italic> in presence/absence IL1A, IL1B, or TNF-a (10 ng/ml) for 24 hr in control (scrambled siRNA) or TRF2-low (TRF2 siRNA) conditions in HT1080 cells. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) Expression of <italic>IL6, IL8,</italic> or <italic>TNF</italic> in control or TRF2-induced conditions on treatment with either IL1A or IL1B (10 ng/ml) for 24 hr in absence (left panel) or presence (right panel) of the IL1-receptor-antagonist IL1RA (20 ng/ml) in HT1080 cells. [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) NFkappaB/phosphor-Ser536-NFKappaB levels in xenograft tumours developed in NOD-SCID mice (control or doxycycline-induced TRF2 in HT1080 cells; N=6 mice in each group) by immuno-flow cytometry; mean fluorescence signal from individual tumours in control or TRF2-induced tumours plotted in adjacent graph; activation shown as ratio of pSer536-p-NFkappaB over total NFkappaB; significance was calculated using Wilcoxon’s non-parametric test. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig6">Figure 6</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig6">Figure 6A and B</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig6">Figure 6A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig6-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>TRF2-dependent IL1 pathway activates NFkappa B (p65) in cancer cells (continued).</title><p>(<bold>A</bold>) TRF2-wild type (WT) and TRF2-2293R mutant proteins fused with dCAS9 expressed and targeted to the IL1R1 promoter using IL1R1-specific gRNA in HT1080 (left) or MDAMB231 cells (right). Following this, NFKB and p-NFKB (Ser536-phosphorylation) levels were assessed by flow-cytometry in ten thousand HT1080 or MDAM231 cells; mean fluorescence signal for IL1R1 and ratio of p-NFKB/total NFKB plotted in graphs on right panels. [N=1]. (<bold>B</bold>) IL1R1 knockout (KO) HT1080 cells using CRISPR were made and were transduced (lentiviral) to a doxycycline-inducible-TRF2 stable line (top left). TRF2, NFKappa-B and Ser536p-NFKappa-B in IL1R1 knockout or control HT1080 cells with or without TRF2 induction by doxycycline; GAPDH used as loading control (top right). Induction of TRF2 in HT1080 WT and IL1R1 KO cells to check for NFkappaB downstream target gene expression (bottom). Activation of NFKB target genes (~two- to fivefold) post-TRF2 over-expression was lower in IL1R1KO cells compared to WT cells (~10tenfold) [N=3] Statistical significance was calculated using Tukey’s multiple comparisons test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) Phospho-NF-Kappa-B-(Ser-536p) and NFkappaB in HT1080 or HT1080-LT cells with or without IL1B stimulation (top panel); ratio of p-NFKB to total NFKB from above western blots plotted from two independent experiments (bottom panel). The NFkappa B (p65/RELA) is detected just below the 70 Kda molecular weight marker. Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>PDF file containing original western blot for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata3"><label>Figure 6—figure supplement 1—source data 3.</label><caption><title>Original image files for western blot for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95106-fig6-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig6-figsupp1-v1.tif"/></fig></fig-group><p>As shown in <xref ref-type="fig" rid="fig5">Figure 5F</xref> (mRNA expression of <italic>IL1R1</italic>), dCas9-TRF2-K293R diminished IL1R1 levels (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>).This resulted in reduced NF-kappaB-Ser536 phosphorylation indicating attenuated NF-kappaB activation in HT1080 and MDAMB 231 cells; dCas9-TRF2 as expected showed activation of IL1R1 and NF-kappaB (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>).</p><p>To directly test the function of IL1R1 in TRF2-mediated NF-kappaB activation, <italic>IL1R1</italic>-knockout (KO; CRISPR-mediated) was made in HT1080 cells having doxycline-inducible-TRF2: NF-kappaB activation (Ser536-phosphorylation), including upregulation of the NF-kappaB-target genes <italic>IL2, IL6,</italic> and <italic>TNF</italic>, was significantly reduced following TRF2 induction in the KO cells compared to HT1080 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Together, these demonstrate the direct role of TRF2 in the induction of IL1 signalling through upregulation of <italic>IL1R1</italic>.</p><p>We reasoned that in cells with longer telomeres IL1 signalling would be affected due to reduced TRF2 binding at the <italic>IL1R1</italic> promoter resulting in attenuated activation of <italic>IL1R1</italic>. In the case of HT1080-LT cells, notable increase in NF-kappaB-Ser536 phosphorylation, following IL1B stimulation, was notably delayed (3 hr in HT10180-LT vs 30 min in HT1080 respectively; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>).</p></sec><sec id="s2-8"><title>IL1R1 expression in TNBC is sensitive to variation in telomere length</title><p>To check if our findings were clinically relevant, we used TNBC tumour samples to characterise telomere length and <italic>IL1R1</italic> expression. The IL1 (interleukin 1) pathway is relevant in TNBC prognosis as indicated by past studies (<xref ref-type="bibr" rid="bib53">Lappano et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Jeon et al., 2016</xref>), and therefore it was relevant for us to use TNBC samples. We checked 94 TNBC samples and variation in telomeres across tumours was evident (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>IL1R1 expression in Triple-Negative Breast cancer (TNBC) samples is sensitive to inter-tumoral variation in telomere length.</title><p>(<bold>A</bold>) Relative telomere length of TNBC samples (94 patients) by Telo-qPCR as reported earlier; signal from telomere-specific primers was normalised to single copy number gene 36B4 for individual samples. All samples were run with HT1080 DNA as control and telomeric signal from HT1080 cells (telomere length ~4.5 Kb) was used as reference for relative measurement; median telomere length (3.6 Kb) shown by red bar; samples &gt;50% or&lt;50% of median (dotted lines) were designated as long or short telomere samples, respectively. [N=94]. (<bold>B</bold>) Flow cytometry analysis of telomere length of TNBC tissues from telomeric signal using telomere–specific FITC-labelled PNA probe; quantification of mean telomeric signal for nine TNBC-ST (short telomere, top left panel) and nine TNBC-LT (long telomere bottom left panel) shown in top right panel. Median telomere length has been indicated by dotted lines (top right). TNBC tissue slides hybridised with telomere-specific PNA probes and counter stained with DAPI. Representative images for long/short telomere TNBC tissue shown (bottom right) [N=9] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) Telomere length was determined using the previously published algorithm Tel-Seq from sequenced genomes of TNBC samples (N=8 for TNBC-ST (short telomere) and N=6 for TNBC-LT (long telomere); and adjacent normal tissue from same patient). Samples identified as long-telomere (TNBC-LT) or short-telomere (TNBC-ST) using telo-qPCR were significantly different in TL, and consistent with telo-qPCR annotation (left); TL of tumour samples was lower that adjacent normal tissue [N=15] (center); and TL from adjacent normal tissues in LT or ST samples did not vary significantly [N=8; N=6](right) Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) Paired telomere length assessment in tumour and adjacent normal tissue for 66 patients. Telomere signal was normalised to 36B4 (single copy gene) by qRT PCR and compared between tumour and adjacent normal samples. The data was plotted pairwise (left) with lines connecting the individual tumor sample to the respective adjacent normal. All samples where tumor telomere length was lower than normal were connected by red lines and the samples where tumour telomeres where higher were connected by blue lines. Relative telomere length (Tumour/Normal) was plotted (middle) with samples with T/N&lt;1 in red and T/N&gt;1 in blue. Out of the 66 samples, 45 samples had T/N&lt;1, suggesting that about two-third of the samples tested had shorter telomeres in the tumours. Analysis of whole genome sequences of 14 pairs of samples using tel-seq pipeline revealed that 11 cases showed lower tumour telomere length compared to their adjacent normal counterparts (right). Left panel-Statistical significance was computed by Wilcoxon matched-pairs signed rank test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) TNBC tissue (N=6 each for long or short telomere samples) stained with EpCAM (far red) and hybridised with telomere-specific PNA probe (FITC). Mean telomeric signal was plotted in total EpCAM<sup>+ve</sup> or EpCAM<sup>–ve</sup> cells. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>F</bold>) mRNA expression of <italic>IL1R1</italic> and other key cytokines: <italic>IL1A, IL1B, IL2, IL6, IL8</italic>, <italic>TNF, IL10, IL4,</italic> and <italic>IL13</italic> in long or short telomere TNBC tissue; the <italic>18</italic> S gene was used for normalization. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>G</bold>) Relative telomere length of triple-negative breast tumour organoids (TNBO) derived from TNBC samples: five TNBO-ST (short telomere) and five TNBO-LT (long telomere) was estimated by telo-qRTPCR. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>H</bold>) mRNA expression of <italic>IL1R1</italic> and other key cytokines in triple-negative breast tumour organoids (TNBO) derived from TNBC samples- TNBO-ST and TNBO-LT; the <italic>18</italic>S gene was used for normalisation. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>I</bold>) Secreted IL1B (pg/ml) from organoids TNBO-ST or TNBO-LT by ELISA using media supernatant form organoid culture (see Materials and methods).[N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>J</bold>) mRNA expression of <italic>IL1R1</italic> and other key cytokines using xenograft tumours made from either short (HT1080) or long telomere (HT1080-LT) fibrosarcoma cells, and ex vivo HT1080 or HT1080-LT cells. The <italic>18</italic>S gene was used for normalisation for the tumours;for ex vivo cells <italic>GAPDH</italic> was used for normalisation. Top panel- [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001).; bottom panel- [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>K</bold>) Heat map summarizing the mRNA expression of key cytokines across the models shown above: TNBC tissue, TNBC derived organoids (TNBO), xenograft tumours or ex vivo cells in long or short telomere cases. Fold change of gene expression (long with respect to short telomeres) color coded as per the reference legend along y-axis. Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig7">Figure 7</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>IL1R1 expression in Triple-Negative Breast cancer (TNBC) samples is sensitive to inter-tumoral variation in telomere length (continued).</title><p>(<bold>A</bold>) TNBC samples (N=6 each for long or short telomere samples) stained with EpCAM (far red) and then hybridised with telomere specific PNA probe (FITC). Mean telomeric signal was plotted in total cells. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>B</bold>) Telomere length was determined using the previously published algorithm Tel-Seq from sequenced genomes of TNBC samples (N=8 for TNBC-ST (short telomere) and N=6 for TNBC-LT (long telomere); and adjacent normal tissue from same patient). Table with sequencing related details of the normal/tumour samples has been provided. (<bold>C</bold>) Telomerase activity was measured from protein lysates across 64 TNBC samples (long or short telomeres) normalised to the telomerase activity of HT1080 cells for the same amount of protein; spearman correlation was calculated between RTL (relative telomere length) and telomerase activity. (<bold>D</bold>) mRNA expression of <italic>hTERT</italic> and <italic>TERC</italic> in six TNBC samples (long or short telomeres) normalised to the <italic>18</italic> S gene in respective samples. [N=6] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) TNBC organoids (TNBO) formed from TNBO-ST (short telomere) and TNBO-LT (long telomere) samples. (<bold>F</bold>) Spearman correlation of,<italic>TERT</italic>, <italic>TERC, IL1R1</italic> and cytokine-related gene expression and RTL (Relative telomere length) in 34 TNBC tissue samples with each other and RTL represented as heat map; gene expression was normalised to the18S gene; for telomere length the 36B4 single-copy gene was used for normalisation (as in <xref ref-type="fig" rid="fig1">Figure 1D</xref>); fold change of TL was calculated with respect to TL in HT1080 cells. (<bold>G</bold>) Overall Survival for breast cancer patients (BRCA) with high IL1R1 mRNA expression [N=254] or low IL1R1 mRNA expression [N=709] from TCGA datasets (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for details) – graph tabulated using cBIOPORTAL with custom queries. Logrank p-value was found to be 0.0149. (<bold>H</bold>) Frequency of occurrence of samples with high / low IL1R1 mRNA expression in various annotated sub-types of breast cancer from TCGA (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for details). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig7-figsupp1-v1.tif"/></fig></fig-group><p>We measured TL (telomere length) in tissues from 94 breast cancer (TNBC) patients: Median TL was ~3.6 kb (quantitative-telomeric-RTPCR; <xref ref-type="bibr" rid="bib69">O’Callaghan et al., 2008</xref>; Telo-qPCR-see Materials and methods; <xref ref-type="fig" rid="fig7">Figure 7A</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Tumours with TL &lt;50% of median were designated TNBC-short-telomeres (TNBC-ST) and &gt;50% of median length TNBC-long-telomeres (TNBC-LT; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). TLs were confirmed by flow cytometry and in situ hybridization (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><p>Further, reads from the whole genome sequence of the TNBC samples were analyzed for estimation of TL using the reported pipline- TelSeq (<xref ref-type="bibr" rid="bib25">Ding et al., 2014</xref>): TL difference between TNBC-ST and LT was clear, and cancer tissue had lower TL than adjacent normal tissue consistent with earlier reports (<xref ref-type="bibr" rid="bib4">Aviv et al., 2017</xref>). We found that, while there were inter-tumour telomere length variations, about ~70% or more (45 out of 66 TNBC samples and 11 out of 14 in tel-seq analysis) samples for which data was available for adjacent normal tissue – showed lower telomere length in tumour samples (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><p>EpCAM<sup>+ve</sup> (tumour-cell marker; <xref ref-type="bibr" rid="bib101">Went et al., 2004</xref>) cells within the TME had significant heterogeneity in TL (lower in TNBC-ST vis-a-vis LT), whereas the difference in TL of EpCAM<sup>-ve</sup> cells was insignificant indicating TL variation in TME was primarily from cancer cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Details for the Tel-seq data have been tabulated with details of TL estimation for individual samples (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). We surprisingly found that telomerase activity negatively correlated with telomere length in TNBC (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>), and while <italic>TERT</italic> was not found to be significantly higher, <italic>TERC</italic> was found to be significantly enhances in TNBC-LT samples (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). This indicates that <italic>TERC</italic> is possibly a more important determinant for telomere length in TNBC.</p><p>Next, along with <italic>IL1R1</italic>, a curated set of pro- and anti-inflammatory cytokines commonly studied concerning tumour immunity (<xref ref-type="bibr" rid="bib39">Homey et al., 2002</xref>; <xref ref-type="bibr" rid="bib12">Briukhovetska et al., 2021</xref>) was screened in TNBC tissue (12 patients- 6 long telomere, 6-short telomere). We found that <italic>IL1R1, IL1B, TNF, and IL3</italic> were lower in long telomere samples (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Patient-derived organoids (TNBC-organoids from short [TNBO-ST] or long [TNBO-LT] telomeres; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>) were made and tested for telomere length. We found that the expected difference in telomere length was observable between the TNBO-ST and TNBO-LT samples (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). When the same set of genes as in <xref ref-type="fig" rid="fig7">Figure 7F</xref> was tested in the TNBO samples, the same trend was observed for <italic>IL1R1</italic>, <italic>IL1B,</italic> and <italic>TNF</italic>. In this case, <italic>IL10</italic> was also lower in TNBO-LT samples (<xref ref-type="fig" rid="fig7">Figure 7H</xref>). Secreted IL1B into the organoid media was also found to be lower in TNBO-LT samples (<xref ref-type="fig" rid="fig7">Figure 7I</xref>). For comparison, the same genes were looked at in HT1080 tumour xenograft and ex vivo cells with long/short telomeres (<xref ref-type="fig" rid="fig7">Figure 7J</xref>).</p><p><italic>IL1B</italic> and <italic>IL1R1</italic> expression was significantly low in the case of tumours/cells with relatively long telomeres and notably consistent across clinical tissue, organoids, xenografts and cells, in contrast to the other cytokines which showed model-specific variation (<xref ref-type="fig" rid="fig7">Figure 7K</xref>). Additionally, mRNA expression correlation from 34 TNBC samples further confirmed the inverse (negative) correlation of <italic>IL1R1</italic> with RTL (relative telomere length) and the consistent positive correlation between <italic>IL1R1</italic> and <italic>IL1B</italic> (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>); showed key IL1 signalling genes largely upregulated in the short-telomere cells. Interestingly, <italic>TRF2</italic> showed a strong positive correlation with <italic>IL1R1</italic> and <italic>IL8</italic> but not with other pro-inflammatory cytokines.</p><p>We, next, used publicly available TCGA gene expression data of breast cancer samples (BRCA; <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) to assess the effect of <italic>IL1R1</italic> expression on cancer prognosis. We categorised samples based on <italic>IL1R1</italic> expression: <italic>IL1R1</italic> high (N=254) and <italic>IL1R1</italic> low samples (N=709). Notably, overall patient survival was significantly lower in <italic>IL1R1</italic> high samples (Log-rank p value: 0.0149; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1G</xref>). We also checked the frequency of occurrence of various breast cancer sub-types in <italic>IL1R1</italic> high and low samples (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1H</xref>). While invasive mixed mucinous carcinoma (the most abundant sub-type) was predominantly seen in <italic>IL1R1</italic> low samples, metaplastic breast cancer was only found within the <italic>IL1R1</italic> high samples. Interestingly, metaplastic breast cancer has been frequently found to be ‘triple negative’, that is ER-, PR-, and HER2- (<xref ref-type="bibr" rid="bib79">Reddy et al., 2020</xref>).</p></sec><sec id="s2-9"><title>Telomere length sensitive IL1R1 expression modulates TAM infiltration in TNBC</title><p>Previous studies have implicated many telomere-sensitive genes to be related to immune regulation (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>). A recent study analyzed transcriptomic data across 31 cancer types to identify genes that are altered with telomere length (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>). The authors found that while sub-telomeric genes (up to 10 MB from the nearest telomeres) were altered with changes in telomere length as previously ascribed to the Telomere position effect (TPE; <xref ref-type="bibr" rid="bib7">Baur et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Pedram et al., 2006</xref>; <xref ref-type="bibr" rid="bib83">Robin et al., 2015</xref>), many ‘telomere-sensitive’ genes were distributed far from telomeres throughout the genome. This is consistent with a previous report that telomeres can affect transcription in regions far beyond sub-telomeres independent of TPE (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). An intriguing observation made by this study was that when the top 500 genes to be altered with telomere elongation were functionally segregated, the highest number of genes fell under the category of ‘Immune response’. When a Gene Ontology analysis was done by us using these genes, ‘macrophage inhibitory factor signalling’ was the top biological process (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). Recent studies have implicated IL1R1-related signalling in M2 TAM infiltration in tumours (<xref ref-type="bibr" rid="bib18">Chen et al., 2023</xref>; <xref ref-type="bibr" rid="bib108">Zhang et al., 2022</xref>). In our data, we had observed consistent change in <italic>IL1R1</italic> and <italic>IL1B</italic> in long versus short telomere tumours and also noted that IL1 signalling has been widely implicated with TAM infiltration in multiple cancers (<xref ref-type="bibr" rid="bib14">Carmi et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Chittezhath et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Lappano et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Mantovani et al., 2019</xref>).</p><p>When breast cancer transcriptomic data from TCGA was segregated into high and low <italic>IL1R1</italic> groups (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Within the differentially expressed genes between high and low <italic>IL1R1</italic> groups, we looked at key immune markers such as reported TAM markers (<italic>CD163, MRC1,D86,CD80</italic>), TAM chemo-attractants (<italic>CCL2, CCL3,CCL5, CCL8,CXCL12</italic>; <xref ref-type="bibr" rid="bib94">Unver, 2019</xref>) as well as reported TIL markers (<italic>CD3G, CD4,CD8A, FOXP3,ENTPD1, PDCD1</italic>; <xref ref-type="fig" rid="fig8">Figure 8A</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). We found that <italic>MRC1</italic> (gene coding for CD206-M2 macrophage marker) was the most significantly upregulated marker in <italic>IL1R1</italic> high samples. Interestingly, <italic>TERT</italic> (often correlated/associated with high telomere length; <xref ref-type="bibr" rid="bib33">Greider, 1998</xref>; <xref ref-type="bibr" rid="bib64">McNally et al., 2019</xref>) was found to be significantly downregulated in <italic>IL1R1</italic> high samples. This observation aligns with our finding that <italic>IL1R1</italic> was higher in short telomere samples in TNBC and TNBO.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Telomere length sensitive IL1R1 expression modulates tumour associated macrophage (TAM) infiltration in TNBC.</title><p>(<bold>A</bold>) Key Immune marker expression (TAM markers, TAM related chemokines, T cell markers), <italic>TERT</italic> and <italic>TERC</italic> were plotted for fold change of transcript level expression (IL1R1 high / IL1R1 low) and adjusted p-values in breast cancer (BRCA) samples categorized as IL1R1 high or low from TCGA (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). (<bold>B</bold>) Percentage TAM infiltration in TNBC tissue with short (TNBC-ST) or long (TNBC-LT) telomeres using markers CD11b and CD206 (CD11b<sup>+</sup>CD206<sup>+</sup> cells shown in top right quadrant); quantification of TAM infiltration from individual TNBC-ST or TNBC-LT samples have been plotted. [N=9] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>C</bold>) TNBC tissue slides stained with TAM-specific marker CD206 for macrophage infiltration within tissue (counterstained with DAPI); representative images for two independent long or short telomere TNBC tissues shown. (<bold>D</bold>) Labelled (red) M2 macrophages derived from THP1 cells incubated with triple-negative breast tissue-derived organoids (TNBO) for 12 hr (scheme in left panel). Infiltration of M2 macrophages in organoids shown as percentage of labelled (red) M2 macrophages in individual flow-cytometry plots (florescence signal (FL3) in x-axis in log scale); percentage infiltration from five TNBO-ST or five TNBO-LT samples shown in right panel. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>E</bold>) Labelled (red) M2 macrophage infiltration in presence/absence of receptor antagonist IL1RA (20 ng/ml) for tumour organoids with short (TNBO-ST) or long telomeres (TNBO-LT) in three replicates; percentage values for M2 infiltration plotted in right panel. Red florescence (FL3; y-axis in log scale) and respective percentage M2 infiltration values marked on top of individual flow cytometry plots. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>F</bold>) mRNA expression of <italic>IL1R1</italic> was checked in presence of varying concentrations of G-quadruplex binding ligands (48 hr treatment) using TNBO. <italic>18</italic> S gene was used for normalisation. Following this, the ligand JD83 was used to check M2 infiltration in TNBO as in (<bold>C, D</bold>). The M2 infiltration has been plotted for control and JD 83 treated samples. Top panel- [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001).; bottom panel- [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig8">Figure 8</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Telomere length sensitive IL1R1 expression modulates tumour associated macrophage (TAM) infiltration in TNBC (continued).</title><p>(<bold>A</bold>) Gene Ontology (GO) analysis of top 500 genes correlated with telomere elongation across 31 cancer types (as reported in <xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>) Top 5 hits for ‘biological processes’ represented in descending order of enrichment; respective fold enrichments shown by individual bars (x-axis – top); the false discovery rate (FDR) shown by blue line. (<bold>B</bold>) Gating strategy for <xref ref-type="fig" rid="fig8">Figure 8B</xref>. (<bold>C</bold>) Gating strategy for CD 45+ve c gated ells and CD 11B+ve gated cells in TNBC. Percentage of CD 45+ve and CD11B+ve (in CD 45+ve population) was checked for TNBC-ST and TNBC-LT samples. [N=5] Statistical significance was calculated using Mann-Whitney’s non-parametric test (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). In the CD11B+ve (in CD 45+ve population), CD 206 (M2 macrophage marker) and CD 86 (M1 macrophage marker)+ve cells were quantified. Percentage of CD 206 high CD 86 low (M2 macrophages) and CD86 high Cd206 low (M1 macrophages) in the myeloid cell population (CD 45+ve CD 11B+ve) was plotted for three TNBC-ST and TNBC-LT samples each. [N=3] Statistical significance was calculated using unpaired T test with Welch’s correction (p values: *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001). (<bold>D</bold>) TNBC tissue (N=6 each for long or short telomere samples) were tested for TERT and TERC expression. The Telomerase activity for these samples was estimated with HT1080 cell lysate as a reference. The normalised values (to the group average) were plotted in a heat map (left) for telomerase activity,TERT and TERC gene expression in the TNBC samples used in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref> along with corresponding % TAM values (top left). The Spearman correlation matrix (top right) and p values (bottom) have been provided. (<bold>E</bold>) CD206 levels by immuno-flow cytometry in THP1 cells and macrophages differentiated from THP1 cells into M0 or M2 types (described in Materials and methods) and plotted along X-axis in log scale (top panel). Bright-field images at ×10 magnification for each cell stage shown in top right panel. (<bold>F</bold>) Different dosages of IL1RA was checked based on previously published reports and the minimal concentration where change in IL1R1 expression was seen (20 ng/ml) was used in other functional assays. [N=1]. (<bold>G</bold>) mRNA expression of IL1R1 was tested in MDAMB-231 cells after a 48 hr treatment with various reported G4-binding ligands. <italic>GAPDH</italic> was used as a normalizing control. [N=2]. Error bars correspond to SEM from independent experiments.</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>Source data for all plots in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> and corresponding details of statistical tests and p-values.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95106-fig8-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig8-figsupp1-v1.tif"/></fig></fig-group><p>With these in mind, we checked TAM infiltration in TNBC-ST vis-à-vis TNBC-LT. Nine TNBC-ST and nine TNBC-LT tumours were analyzed for M2-type TAMs by double-positive CD11b (monocyte-derived cells; <xref ref-type="bibr" rid="bib15">Cassetta et al., 2016</xref>) and CD206 (M2-specific; <xref ref-type="bibr" rid="bib46">Jaynes et al., 2020</xref>) labelling: TNBC-LT had relatively low TAM infiltration (mean 1.78%, range: 0.18–5.41%) than TNBC-ST (mean 7.34%, range: 3.76–16.80%; <xref ref-type="fig" rid="fig8">Figure 8B</xref>; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>). Accordingly, CD206 expression was found to be lower in tissue sections from TNBC-LT relative to TNBC-ST tumours (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). We further found that the total proportion of immune cells (% of CD45 +ve) did not vary significantly between short and long telomere TNBC samples (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>). However, TNBC-ST samples had a higher percentage of myeloid cells (CD11B+ve) within the CD 45+ve immune cell population. We checked in three TNBC-ST and TNBC-LT samples and found that the percentage of M1 macrophages (CD86 <sup>high</sup> CD 206 <sup>low</sup>) in the myeloid population was lower than that of the M2 macrophages (CD 206 <sup>high</sup> CD 86 <sup>low</sup>) and unlike the latter, did not vary significantly between TNBC-ST and TNBC-LT samples (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>).</p><p>We used the available data for <italic>TERT/TERC</italic> expression for a subset of the samples and plotted the telomerase activity for these TNBC samples (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>). Upon checking we found that while <italic>TERT</italic> did not significantly correlate with either telomere length or telomerase activity, the correlation with <italic>TERC</italic> was significant with telomere length. <italic>TERC</italic> was earlier shown to vary significantly between short and long-telomere TNBC samples (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Therefore, in TNBC, <italic>TERC</italic> seems to be critical for telomere length. Individually, neither <italic>TERT</italic> nor <italic>TERC</italic> correlated significantly with % TAM in TNBC tissue. As expected from our other results, % TAM correlated significantly with RTL. This indicates that in TNBC tissue, telomere length is possibly a more important determinant for TAM infiltration than either <italic>TERT</italic>, <italic>TERC</italic> or telomerase activity.</p><p>TAM infiltration was further tested using patient tumour-derived organoids from five long and five short telomere cases. M2-type macrophage derived from THP1 cells (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1E</xref>) were labelled (red-tracker dye) before co-incubating with each of the five TNBO-ST or five TNBO-LT: Following 12 hr incubation TNBO-ST had on average 8.56% infiltration of M2-type macrophages (range: 6.54–10.9%) compared to 3.14% (range: 0.99–4.88%) for TNBO-LT (<xref ref-type="fig" rid="fig8">Figure 8D</xref>).</p><p>Further, we used the IL1R1-receptor antagonist IL1RA to directly test IL1R1 dependence. The minimum dosage of IL1RA where expression of inflammatory markers was found to be altered in TNBO was used in the assays (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1F</xref>). Organoids treated with IL1RA before co-incubating with dye-labelled M2-type macrophages showed &gt;50% reduction in macrophage infiltration (<xref ref-type="fig" rid="fig8">Figure 8E</xref>).</p><p>Finally, we screened several G4 binding ligands in MDAMB231 cells and found that a few ligands (JD83, 12459, and NMM) could reduce <italic>IL1R1</italic> expression (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1G</xref>). These ligands were tested in TNBO and we found JD83 to be effective in reducing <italic>IL1R1</italic> expression at 5 µM concentration (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). We found that JD83 is also effective in reducing M2 migration in TNBO, showing promise for future therapeutic interventions.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Recently, we described the TL-sensitive expression of genes distant from telomeres (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>). Cells with relatively long telomeres sequestered more TRF2 at the telomeres affecting non-telomeric binding, and vice-versa. Proposed as the telomere-sequestration-partition (TSP) model (<xref ref-type="bibr" rid="bib95">Vinayagamurthy et al., 2020</xref>), this is independent of telomere-positioning-effect (TPE) on expression of sub-telomeric genes (up to 10 Mb from telomeres; <xref ref-type="bibr" rid="bib82">Robin et al., 2014</xref>). TL-dependent <italic>IL1R1</italic> activation by non-telomeric TRF2 is in tune with the TSP model. It needs to be noted that the <italic>IL1R1</italic> gene is located above 100 MB away from the nearest telomere in humans, and hence far out of the proposed 10 MB range of the TPE model. Altered transcription when telomere maintenance is affected in varied contexts (<xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>; <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>), particularly across 31 cancer types (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>), appears consistent with TSP and support our observations related to TL-dependent IL1 signalling. A model of telomere length and TRF2-dependent <italic>IL1R1</italic> expression and the potential modulation of TAM infiltration is presented as a graphical summary (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Graphical summary.</title><p>Scheme depicting relatively low infiltration of TAM in tumours with relatively long telomeres vis-à-vis tumours with short telomeres. Reduced non-telomeric TRF2 binding at the IL1R1 promoter in tumours with long telomeres, and consequent low IL1R1 activation, attenuated p65-mediated IL1-beta and macrophage infiltration. Created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/w69h958">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95106-fig9-v1.tif"/></fig><p>Besides TRF2, the non-telomeric function of the shelterin protein RAP1 has been reported as part of complex with NF-kappaB (<xref ref-type="bibr" rid="bib93">Teo et al., 2010</xref>). Although TRF2 has been implicated in influencing Natural Killer (NK) cells and infiltration of myeloid derived immuno-suppressive cells (MDSC; <xref ref-type="bibr" rid="bib10">Biroccio et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Cherfils-Vicini et al., 2019</xref>) underlying mechanisms were unclear. However, the function of non-telomeric TRF2 in either IL1 signalling or in a telomere-sensitive role in immune signalling, has not been previously studied.</p><p>Mechanistically, we found that DNA secondary structure G4s present on the <italic>IL1R1</italic> promoter are necessary for TRF2 binding. Perturbation of the G4s genetically by destabilizing base substitutions, or upon using small molecules that bind to G4 inside cells resulted in reduced promoter TRF2 binding and <italic>IL1R1</italic> expression. This is in line with our earlier results showing G4-dependent non-telomeric TRF2 binding throughout the genome, and how TRF2 recruitment to specific promoters leads to epigenetic histone modifications (<xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Sharma et al., 2021</xref>). We recently noted the transcription repression of telomerase (<italic>hTERT</italic>) to be TRF2-mediated in a PRC2-repressor-dependent fashion (<xref ref-type="bibr" rid="bib88">Sharma et al., 2021</xref>). This, interestingly, suggests the emerging role of TRF2 as a transcriptional modulator with repressor/activator (as shown here) functions depends on cofactor engagement that is possibly contextual.</p><p>The histone-modifying enzyme complex-p300/CBP have been keenly studied in cancer epigenetics specifically breast cancers (<xref ref-type="bibr" rid="bib43">Iyer et al., 2004</xref>; <xref ref-type="bibr" rid="bib78">Ramadan et al., 2021</xref>; <xref ref-type="bibr" rid="bib80">Ring et al., 2020</xref>). Recent findings also show acetylated H3K27 enrichment at the telomeres through p300-dependent HAT activity (<xref ref-type="bibr" rid="bib23">Cubiles et al., 2018</xref>); however, role of TRF2 in p300 engagement or H3K27 acetylation at the telomeres was not investigated. Here, notably, we found TRF2-dependent p300 recruitment, and HAT activity resulting in H3K27 acetylation at the <italic>IL1R1</italic> promoter. Together, these support the role of non-telomeric TRF2 as an activating transcription factor through p300 implicating a broader role of TRF2-p300-dependent histone modifications in cancer. Further, these suggest the possibility of similar functions of telomeric TRF2 in H3K27 acetylation at the telomeres (<xref ref-type="bibr" rid="bib23">Cubiles et al., 2018</xref>). The lysine residue K293 acetylation on TRF2 seems to be crucial for p300-TRF2 interaction.</p><p>It has been noted previously that TERT can have effects on NF-kappa B signalling independent of telomere length alterations (<xref ref-type="bibr" rid="bib29">Ghosh et al., 2012</xref>). We observed that in long telomere HT1080-LT cells, while NF-kappa B signalling was retarded- a late surge of NFKappa-B activation occurred. We are inclined to think this could be a potential effect of TERT over-expression. Understanding the extent to which TERT influences the inflammatory signalling in TNBC independent of telomere length would require further work.</p><p>IL1 signalling in relation to inflammation in cancer has been extensively studied and consequently, IL1B blockers and the receptor antagonist IL1RA are of clinical interest (<xref ref-type="bibr" rid="bib39">Homey et al., 2002</xref>; <xref ref-type="bibr" rid="bib21">Chittezhath et al., 2014</xref>; <xref ref-type="bibr" rid="bib5">Balkwill and Mantovani, 2001</xref>; <xref ref-type="bibr" rid="bib50">Kaplanov et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Lappano et al., 2020</xref>). Further, the effect of altered IL1 signalling on M2-type TAM infiltration was reported in multiple cancer types (<xref ref-type="bibr" rid="bib16">Chanmee et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Hu et al., 2016</xref>). TAM infiltration has been consistently linked to tumour aggressiveness (<xref ref-type="bibr" rid="bib70">Oner et al., 2020</xref>) and recent work on targeting (<xref ref-type="bibr" rid="bib54">Lee et al., 2019</xref>; <xref ref-type="bibr" rid="bib84">Rogers and Holen, 2011</xref>) and modifying TAMs from M2-like states to a more anti-tumourigenic M1-like states (<xref ref-type="bibr" rid="bib46">Jaynes et al., 2020</xref>) have shown promise as strategies for intervention in cancer. The clinical significance of blocking IL1 signalling in cancers has been widely reported (<xref ref-type="bibr" rid="bib12">Briukhovetska et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Kaplanov et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Mantovani et al., 2018</xref>). Based on our findings, we attempted TRF2-mediated single-gene-targeted epigenetic silencing of <italic>IL1R1</italic> in cell lines and ligand-based approaches in TNBC organoids. A combination of single gene editing and small molecule/ ligand-based intervention might be useful in therapy.</p><p>For the functional significance of TL in TME, we focused on IL1-signalling and TAM. Results from TNBC organoids here show that blocking IL1R1 using IL1RA was sufficient for restricting M2 infiltration (<xref ref-type="fig" rid="fig8">Figure 8E</xref>) suggesting that the IL1 signalling within the tumour cell is important. However, particularly because macrophages are known to be a rich source of IL1B (<xref ref-type="bibr" rid="bib14">Carmi et al., 2009</xref>; <xref ref-type="bibr" rid="bib2">Arango Duque and Descoteaux, 2014</xref>; <xref ref-type="bibr" rid="bib61">Mantovani et al., 2018</xref>), and given the model-specific changes in inflammatory cytokines noted by us, further experiments will be required to understand how telomeres influence paracrine/ juxtracrine IL1 signalling between cancer cells and TAM.</p><p>It is quite possible that TL affects tumour-immune signalling through other immune cell types as well [implied by altered immune-response genes in TL-dependent gene-expression analysis (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>)] and/or influences the nature of TAM (<xref ref-type="bibr" rid="bib41">Hung et al., 2016</xref>), which is known to vary contextually (<xref ref-type="bibr" rid="bib60">Mantovani and Locati, 2013</xref>). These possibilities, together with the well-established effect of IL1-targeting in improving cancer prognosis (<xref ref-type="bibr" rid="bib12">Briukhovetska et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Cristofari and Lingner, 2006</xref>; <xref ref-type="bibr" rid="bib62">Mantovani et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Mantovani et al., 2018</xref>) underline the need for further work to attain a deeper understanding of telomere-sensitive IL1 signalling in the TME.</p><p>Although we observed a range of telomere lengths across cancers in TNBC patients (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>), as also noted by other groups (<xref ref-type="bibr" rid="bib56">Londoño-Vallejo, 2004</xref>; <xref ref-type="bibr" rid="bib74">Pellatt et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Shen et al., 2007</xref>; <xref ref-type="bibr" rid="bib102">Wentzensen et al., 2011</xref>; <xref ref-type="bibr" rid="bib103">Willeit et al., 2010</xref>), tumours largely have been reported to maintain shorter telomeres than normal tissue (<xref ref-type="bibr" rid="bib4">Aviv et al., 2017</xref>). Here, we found that tumour cells with shorter TL-activated IL1 signalling increase M2-type TAM infiltration, which is known to aid immunosuppression (<xref ref-type="bibr" rid="bib1">Allavena et al., 2008</xref>). Based on our results, and other reports suggesting immunomodulation in cancers with relatively short telomeres (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Hirashima et al., 2013</xref>), it is therefore tempting to speculate that short-telomere cancer cells might be ‘selectively’ better equipped to evade host immune cells. To sum up- our work reveals new molecular connections between telomeres and tumour immunosuppression, presenting a conceptual framework for a better understanding of patient-specific responses to cancer immunotherapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HT0180</td><td align="left" valign="bottom">Human</td><td align="left" valign="bottom">ATCC -CCL-121</td><td align="left" valign="bottom">Fibrosarcoma</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDAMB231</td><td align="left" valign="bottom">Human</td><td align="left" valign="bottom">ATCC HTB-26</td><td align="left" valign="bottom">Breast cancer</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">Human</td><td align="left" valign="bottom">ATCC CRL-3216</td><td align="left" valign="bottom">Embryonic kidney derived</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MRC5</td><td align="left" valign="bottom">Human</td><td align="left" valign="bottom">ATCC CCL-171</td><td align="left" valign="bottom">Immortalized fibroblast</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">THP1</td><td align="left" valign="bottom">Human</td><td align="left" valign="bottom">ATCC TIB-202</td><td align="left" valign="bottom">Monocyte derived from peripheral blood from an acute monocytic leukemia patient</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">R-Spondin 3</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">3500-RS/CF</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Neuregulin 1</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–03</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGF 7</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–19</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGF 10</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–26</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">EGF</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">AF-100–15</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Noggin</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">120–10 C</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">A83-01</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">2939</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">Abmole</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SB202190</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">S7067</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">B27 supplement</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">17504–44</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">N-Acetylcysteine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">A9165-5g</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Nicotinamide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">N0636</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">GlutaMax 100 x</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">12634–034</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Hepes</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">15630–056</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Penicillin/Streptomycin</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">15140–122</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Primocin</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Ant-pm-1</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Advanced DMEM/F12</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">12634–034</td><td align="left" valign="bottom">TNBC organoid culture reagent</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TRF2<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">(Novus NB110-57130)-</td><td align="left" valign="bottom">ChIP (1:100), IP (1:100), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TRF2<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">(Millipore 4A794)-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TRF1<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">(Novus NB110-68281)-</td><td align="left" valign="bottom">WB (1:1000), IP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IL1R1<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(abcam ab106278)-</td><td align="left" valign="bottom">IF (1:500), Flow cytometry (1:500), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DDK/FLAG<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">(Sigma-F1804)-</td><td align="left" valign="bottom">ChIP (1:100), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BG4 (recombinant antibody)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">(Sigma Aldrich MABE917)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P300<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST D2X6 N)</td><td align="left" valign="bottom">ChIP (1:100), IP (1:100), IF (1:1000), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ac-p300/CBP<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 4771)</td><td align="left" valign="bottom">ChIP (1:100), IP (1:100), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CBP<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 7389)</td><td align="left" valign="bottom">ChIP (1:100), WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P65(NFKB)<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 8242)</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ser536 P p65 NFKB<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 3033)</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IKB<break/>(mouse monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 4814)</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-IKB<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 2589)</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD44<break/>(mouse monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">(CST 3570)</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Histone H3<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(Abcam ab1791)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">H3K27ac<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(Abcam ab4729)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">H3K4me3<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(Abcam ab8580)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">H3K27me3<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(abcam ab192985)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">H3K9me3<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">(abcam ab8898)-</td><td align="left" valign="bottom">ChIP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Beta-actin<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Santa-cruz</td><td align="left" valign="bottom">(Santacruz C4)-</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Santa-cruz</td><td align="left" valign="bottom">(Santacruz 6C5)-</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11b<break/>(mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">(ICRF44), eBioscience-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD206<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">(MR5D3) Invitrogen-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-human CD326 (EpCAM)<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">(9C4) BioLegend-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-human CD11B<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">(ICRF44) BioLegend-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-human CD45<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">(HI30) BioLegend-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-Cy7 anti-human CD45<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">(W17233E) BioLegend-</td><td align="left" valign="bottom">Flow cytometry (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Rabbit IgG (rabbit polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">(Millipore 12-370)</td><td align="left" valign="bottom">isotype control (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IgG<break/>(mouse polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">(Millipore 12–371)</td><td align="left" valign="bottom">isotype control (1:100)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV6-myc-DDK(FLAG)-TRF2 vector (TRF2 WT)</td><td align="left" valign="bottom">origene</td><td align="left" valign="bottom">RC223601</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">TRF2 shRNA</td><td align="left" valign="bottom">origene</td><td align="left" valign="bottom">TL308880</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">dCAS9-VP64-GFP</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">61422</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pX333</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">64073</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pENTR11</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">K253520</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCW57.1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">41393</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">TERC shRNA</td><td align="left" valign="bottom">Santa-cruz</td><td align="left" valign="bottom">sc-106994-SH</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">PGL3 basic</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">E1751</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pGL4.73</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">E611</td><td align="left" valign="bottom">Plasmid</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines, media, and culture conditions</title><p>HT1080 fibrosarcoma derived cell line was purchased from ATCC. HT1080-LT cells (<xref ref-type="bibr" rid="bib22">Cristofari and Lingner, 2006</xref>) were a kind gift from Dr. J. Ligner. HT1080 and MRC5 (purchased from ATCC) cells and corresponding telomere elongated cells were maintained in Modified Eagle’s medium (MEM; Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (FBS; Gibco). MDAMB231 (gift from Mayo Clinic, Minnesota, USA) and HEK293T (purchased from NCCS, Pune) cells were maintained in DMEM-HG (Dulbecco’s Modified Eagle’s medium - High Glucose; Sigma-Aldrich) with a supplement of 10% FBS. All THP1 cell lines (gift from Dr Vivek Rao, IGIB, Delhi and subsequently purchased from NCCS, Pune) and derivative cell types were maintained in RPMI with 10% FBS and 1 X Anti-Anti (anti-biotic and anti-mycotic from Thermo Fisher Scientific). All cultures were grown in incubators maintained at 37 °C with 5% CO<sub>2</sub>. All stable lines generated from these cell types were maintained in the same media with 1 X Anti-Anti.</p></sec><sec id="s4-2"><title>Processing of tumour/xenograft tissue</title><p>Tissues collected for this study were stored in RNA later (Sigma-Aldrich) at –80 °C. Approximately 10 milligrams of tumour tissue were weighed and washed thrice with ice-cold 1 X PBS- 1 ml (filtered). About 300 µl of PBS was left to submerge the tissue after the final wash. Using a sanitised razor blade, the tumour was cut into small pieces (the efficiency of the digestion is dependent on how well the tumour is minced; large pieces will not digest properly and may need extra digestion time). The tumour soup was transferred into a 15 ml tube using a P1000 pipette (cut the top of the tip to be able to take all the tissue) and the volume was adjusted to 4 ml of 1 X pre-chilled PBS. 80 µl of Liberase TL stock solution (Roche) was mixed using a vortex and incubated for 45 min at 37 °C under continuous rotation. The sample was checked visually; the cell suspension should look smooth (if the cell suspension still contains tissue fragments digest for an additional 15 min). To end the enzymatic digestion,10 ml PBS with 1 % w/v BSA (Sigma-Aldrich) was added. The cells were filtered using a 100 µm cell strainer in a 50 ml tube and the volume adjusted to 20 ml with 1 X PBS (pre-chilled). Cells were centrifuged for 7 min at 500 × <italic>g</italic> and 4 °C. The supernatant was discarded and the cells were re-suspended in 1 ml serum-free media. Subsequently, cells were counted and volume was made up to get a cell density of 1 million cells/ml. Following this, the cell suspension was used for ChIP, DNA/RNA isolation, and flow cytometry.</p></sec><sec id="s4-3"><title>Organoid generation and culture</title><p>TNBC tissue was used to make tumour organoids using the following protocol:</p><list list-type="order"><list-item><p>The fresh tissue was stored in 5 ml of Media 1 (Advanced DMEM F12 +1 X Glutamax +10 mM HEPES +1 X AA).</p></list-item><list-item><p>1–3 mm<sup>3</sup> tissue piece was cut, washed and minced in 10 ml (Media 1).</p></list-item><list-item><p>The minced tissue was digested overnight on a shaker in Media 1 with 1–2 mg/ml of collagenase.</p></list-item><list-item><p>After overnight incubation the digested tissue was sequentially sheared using a 1 ml pipette.</p></list-item><list-item><p>After each shearing step, the suspension was strained using a 100 µm filter to retain tissue pieces. Thus entering in subsequent shearing step with approximately 10 ml Advanced DMEM F12.</p></list-item><list-item><p>To this, 2% FCS was added and centrifuged at 400 × <italic>g</italic>.</p></list-item><list-item><p>The pellet was resuspended in 10 mg/ml cold cultures growth factor reduced BME Type 2 and 40 µl drops of BME suspension was allowed to solidify on pre-warmed 24well culture plates at 37 °C 5% CO<sub>2</sub> for 30 min.</p></list-item><list-item><p>Upon complete gelation 400 µl of BC organoid medium was added to each well and plates transferred to 37 °C 5% CO<sub>2</sub>.</p></list-item></list><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Medium component</th><th align="left" valign="bottom">Supplier</th><th align="left" valign="bottom">Catalogue number</th><th align="left" valign="bottom">Final concentration</th></tr></thead><tbody><tr><td align="left" valign="bottom">R-Spondin 3</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">3500-RS/CF</td><td align="left" valign="bottom">250 ng·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">Neuregulin 1</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–03</td><td align="left" valign="bottom">5 nM</td></tr><tr><td align="left" valign="bottom">FGF 7</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–19</td><td align="left" valign="bottom">5 ng·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">FGF 10</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">100–26</td><td align="left" valign="bottom">20 ng·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">EGF</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">AF-100–15</td><td align="left" valign="bottom">5 ng·ml<sup>-1 a</sup></td></tr><tr><td align="left" valign="bottom">Noggin</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">120–10 C</td><td align="left" valign="bottom">100 ng·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">A83-01</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">2939</td><td align="left" valign="bottom">500 nM</td></tr><tr><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">Abmole</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">5 mM</td></tr><tr><td align="left" valign="bottom">SB202190</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">S7067</td><td align="left" valign="bottom">500 nM <sup>b</sup></td></tr><tr><td align="left" valign="bottom">B27 supplement</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">17504–44</td><td align="left" valign="bottom">1x</td></tr><tr><td align="left" valign="bottom">N-Acetylcysteine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">A9165-5g</td><td align="left" valign="bottom">1.25 mM</td></tr><tr><td align="left" valign="bottom">Nicotinamide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">N0636</td><td align="left" valign="bottom">5 mM</td></tr><tr><td align="left" valign="bottom">GlutaMax 100 x</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">12634–034</td><td align="left" valign="bottom">1x</td></tr><tr><td align="left" valign="bottom">Hepes</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">15630–056</td><td align="left" valign="bottom">10 mM</td></tr><tr><td align="left" valign="bottom">Penicillin/Streptomycin</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">15140–122</td><td align="left" valign="bottom">100 U·ml<sup>–1</sup>/100 mg·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">Primocin</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Ant-pm-1</td><td align="left" valign="bottom">50 mg·ml<sup>–1</sup></td></tr><tr><td align="left" valign="bottom">Advanced DMEM/F12</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">12634–034</td><td align="left" valign="bottom">1x</td></tr></tbody></table></table-wrap><p>9. The media was changed every fourth day.</p><p>10. The culture was grown for 10 days before passaging.</p><p>II. Passaging organoid cultures</p><list list-type="order"><list-item><p>Cultrex growth factor reduced BME Type 2 geltrex was thawed overnight on ice at 4 °C.</p></list-item><list-item><p>Media was removed from the organoid wells and washed twice with PBS-EDTA.</p></list-item><list-item><p>For each well of 24-well plate 300 µl of TrypLE was added and incubated at 37 °C 5% CO<sub>2</sub> for 5 min.</p></list-item><list-item><p>600 µl of washing media (DMEM F12) was added and organoids were dissociated vigorously by pipetting.</p></list-item><list-item><p>Organoid solution was transferred to 15 ml falcon with 5 ml washing media and centrifuged at 1000 rpm for 5 min to pellet organoids.</p></list-item><list-item><p>Supernatant was carefully aspirated leaving behind 200 µl media and 500 µl of fresh media, mixed well gently and transferred to 1.5 ml tube for centrifugation at 650 × <italic>g</italic> for 5 min at 4 °C.</p></list-item><list-item><p>Supernatant was gently aspirated and resuspended in cold cultrex and 40 µl drop/well was seed in a pre-warmed 24well plate.</p></list-item><list-item><p>Incubated for 30 min and add 400 µl of BC organoid medium.</p></list-item></list></sec><sec id="s4-4"><title>M2 macrophage generation from THP1 cells</title><p>THP1 cells (0.5 million cells in 1 ml) were seeded in a 35 mm dish and treated with PMA (10 ng/ml; Sigma-Aldrich) for 24 hr in RPMI complete media (+10% FBS; Gibco). PMA was removed and cells were cultured for 48 hr in RPMI to get semi-adherent M0 cells. Following this, cells were treated with IL4 (10 ng/ml; Gibco) and IL13 (20 ng/ml; Gibco) for 24 hr in RPMI complete media. Cells were checked for expected morphological changes and trypsinized for use as M2 macrophages.</p></sec><sec id="s4-5"><title>M2 macrophage infiltration assay in TNBC tumour organoids</title><p>M2 macrophages were labelled with Cell Tracker red dye (Thermo Fisher Scientific) for 30 min and the excess dye was washed off. 10000 labelled M2 macrophages in 20 µl 1 X PBS were introduced in a 96-well with TNBC organoids in a dome with supplement enriched media (200 µl). 12 hr later, the media was washed off with three 1X PBS washes and the organoid dome was extracted with 100 µl TrypLE (Gibco) and resuspended with 100 µl chilled 1 X PBS. This cocktail was kept on ice for 5 min and centrifuged at 1000 × <italic>g</italic> for 10 min. The supernatant was removed and the process was repeated.</p><p>The cells were resuspended in 500 µl chilled 1 X PBS and subjected to Flow-cytometric analysis for scoring percentage of labelled (red) M2 macrophages infiltrating the organoids.</p></sec><sec id="s4-6"><title>Xenograft tumour generation in NOD-SCID mice</title><p>The xenograft tumour generation in NOD SCID tumours was outsourced to a service provider (Vivo Bio TechLtd – Telangana, India). 2.5 million cells (HT1080, HT1080-LT or HT1080-TRF2 inducible) were subcutaneously injected in healthy male mice (4–6 weeks old) and tumour growth was allowed. In case of TRF2 inducible HT1080 cells, tumours were allowed to grow to 100 mm<sup>3</sup> before oral dosage of doxycycline (or placebo control) was started at 2 mg/kg of body weight of mice. Mice were sacrificed to obtain tumours when tumours reached an average volume of 600 mm<sup>3</sup>(±100).</p></sec><sec id="s4-7"><title>Telomeric fluorescent in situ hybridization (FISH)</title><p>Telomere-specific PNA probe [TelC-FITC-F1009-(CCCTAA)n from PNABio] was used following the manufacturer protocol with minor modifications. Briefly, the cells grown in chamber slides up to ~70% confluency and were treated with RNase solution for 5–10 min in 1 X PBS at room temperature. For tissue section, rehydrated tissue sections on slides were used prior to RNase treatment. Slides were washed in chilled PBS twice followed by dehydration with an increasing concentration of ethanol gradient. Slides were briefly warmed at 80 °C and then 250 nM PNA was added with hybridisation buffer (20 mM Tris, pH 7.4, 60% formamide (Sigma-Aldich), 0.5% of 10% Goat Serum). Slides were heated and covered with the buffer at 85 °C for 10 min, kept at room temperature in a dark humid chamber for 4 hr to overnight to facilitate slow cooling and hybridisation. The unbound PNA was washed with wash buffer (2 X SSC, 0.1% Tween‐20 (Thermo Fisher Scientific)) followed by PBS wash twice. DAPI solution (Sigma-Aldrich) was added for 5 min and then the slides were washed in PBS. ProLong Gold Antifade Mountant (Thermo Fisher Scientific) was added and the section was covered with a cover glass. Imaging was done with a Leica SP8 confocal microscopy system. Images were analyzed using open source image analysis software Fiji (Image J, <ext-link ext-link-type="uri" xlink:href="https://imagej.net/software/fiji/">imagej.net/software/fiji/</ext-link>).</p></sec><sec id="s4-8"><title>DNA and RNA extraction from TNBC/xenograft tissue</title><p>Allprep DNA/RNA Universal kit (QAGEN) was used as per manufacturer’s suggested protocol for extraction of DNA and RNA from single cell suspension prepared from tissues as described before.</p></sec><sec id="s4-9"><title>Telo-qPCR</title><p>For telomere length assessment by qRT PCR, telomere-specific primers and single copy number gene 36B4 for normalisation was used in PCR reactions with sample DNA using reported protocol (<xref ref-type="bibr" rid="bib69">O’Callaghan et al., 2008</xref>).</p><p>The primers used are as follows:</p><list list-type="simple"><list-item><p>Tel F <named-content content-type="sequence">CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT</named-content></p></list-item><list-item><p>Tel R <named-content content-type="sequence">GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT</named-content></p></list-item><list-item><p>36B4F <named-content content-type="sequence">CAGCAAGTGGGAAGGTGTAATCC</named-content></p></list-item><list-item><p>36B4R <named-content content-type="sequence">CCCATTCTATCATCAACGGGTACAA</named-content></p></list-item></list><p>The relative telomere length of TNBC patient tissue samples were estimated by normalizing to telomere signal of HT1080 fibrosarcoma cells (reference cell type) as follows:</p><list list-type="simple"><list-item><p>Telomere signal = 2 <sup>-(Ct Tel – Ct 36B4)</sup></p></list-item><list-item><p>Relative telomere length (RTL)=Telomere signal (sample) / Telomere signal (reference).</p></list-item></list></sec><sec id="s4-10"><title>Flow-cytometry</title><p>The procedure for Flow-cytometry was adapted from basic flow cytometry guidelines from CST and has been previously reported in <xref ref-type="bibr" rid="bib88">Sharma et al., 2021</xref>. The cell suspension was fixed with 4% formaldehyde and permeabilised with 0.1% triton X (in 1XPBS) for nuclear proteins. Incubation of primary antibody (1:500 v/v in 1% BSA in 1 X PBS) for 1 µg/ml antibody concentration for 2 hr at RT or at 4°C overnight, was followed by PBS wash (three times) and fluorescently labelled secondary antibody (1:1000 v/v) for 2 hr at RT. Following this, cells were washed with 1 X PBS (three times) and re-suspended in 1XPBS for flow-cytometric analysis using BD Accuri C6 or BD FACSAria III. Equal number of events (10000 for most of the analysis) were recorded for calculating percentage infiltration.</p><p>For single channel analysis, histogram prolife (log scale) was generated in ungated sample-SSC-FSC plots. For quadrant gating for double positive cells (two channels), biex- scale plots or log scale were used. All statistics like mean fluorescence intensity and standard deviation were estimated using built-in tools for analysis in the software FlowJo.</p></sec><sec id="s4-11"><title>Relative telomeres length (RTL) by flow cytometry</title><p>The RTL value is calculated as the ratio between the telomere signal of each sample and the control cell. The Telomere PNA Kit/FITC kit from Dako (Agilent) was used to estimate Telomere length signal in samples. The process has been previously standardised and reported (<xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>).</p></sec><sec id="s4-12"><title>TelSeq- estimation of telomere length using sequencing data</title><p>We used TelSeq (<xref ref-type="bibr" rid="bib25">Ding et al., 2014</xref>) to estimate the average TL for each tumour and normal sample in our dataset. TelSeq was run with default parameters using WGS (whole genome Sequencing) samples with coverage ≥30 X, except the read length parameter (-r) which was set to 150 to match with our data. Briefly, the TL was calculated as the total number of reads containing seven or more telomeric repeats (‘TTAGGG’) divided by the total number of reads with GC content 48–52%. Further, the resultant value was multiplied with a constant value to account for genome size and the number of telomeric ends. This was done separately for each read group within a sample, and then the weighted average was calculated for each sample by taking into account the number of reads per group (as weights).</p><p>The estimated average TL (represented in Kilobase-pair [Kb] units) for tumour and normal samples has been provided in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>. Overall, we found that the tumour samples have lower TL scores (Median: 3.20 Kb) as compared to the matched normal samples (Median: 4.67 Kb). Also, the TL estimates from our tumour samples (Median: 3.20 Kb, range:2.3–21.10 Kb) were comparable to the TCGA breast cancer cohort (WGS; Median: 3.5 Kb, range: 1.4–29.7 Kb) analyzed by <xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>.</p><p>To check if the tumour samples with high TL estimates were confounded by the aneuploidy and tumour purity (which was not taken into account in the TelSeq analysis), we computed the purity and ploidy values for each tumour sample (where possible) using ASCAT (<xref ref-type="bibr" rid="bib77">Raine et al., 2016</xref>) through Sarek pipeline (<xref ref-type="bibr" rid="bib27">Garcia et al., 2020</xref>). However, we found no significant difference in the purity (Wilcoxon test two-sided p<italic>=</italic>0.25) and ploidy (Wilcoxon test two-sided p<italic>=</italic>0.52) values between tumour samples with high versus low TL scores, suggesting that the tumours with high TL estimates were not influenced by these parameters.</p></sec><sec id="s4-13"><title>IL1B and IL1RA treatment</title><p>Reconstituted IL1B (Sigma-Aldrich) was treated to appropriate cells at 10 ng/ml concentration followed by assays. Similarly, IL1RA (Abcam) was treated to appropriate cell/TNBO at 20 ng/ml concentration followed by assays at appropriate time points in specific experiments.</p></sec><sec id="s4-14"><title>IL1B ELISA</title><p>IL1B ELISA was performed using Human IL-1 beta/IL-1F2 DuoSet ELISA kit by R&amp;D Biosystems. As per manufacturer’s protocol 96-well microplate was coated with100ul per well of freshly prepared Capture Antibody diluted 100 times in PBS without carrier protein. Thereafter the plate was sealed and incubated overnight at room temperature. The following day, the capture antibody was aspirated after which each well was washed three times with 1 X Wash Buffer (PBST). After the last wash, the remaining wash buffer was removed carefully and completely by aspiration and blotting it against clean paper towels. The prepped, empty wells were blocked at room temperature for 1 hr by adding 300 μL of Reagent Diluent (20% BSA in 1 X PBST) to each well. Wash the wells as in the step above. Next we added the samples and standard protein of known increasing concentrations (100 μl in volume) diluted in Reagent Diluent. The plates were then covered with an adhesive strip and incubated for 2 hr at room temperature. Post incubation, the wells were washed as above for plate preparation. Following the washes, we added 100 μl of freshly prepared Detection Antibody diluted 100 times in PBS. The plate was covered and incubated for 2 hr at room temperature. Post incubation the wells were washed thrice as in the previous step. Finally for generating detectable signal, we added 100 μl of Streptavidin-HRP to each well, covered the plate and incubated it in dark at room temperature for 20 min. Next the wells were washed thrice as in steps above. After aspirating the wells clean of any buffer we added 100 μl of Substrate Solution to each well and incubated the plates again in dark at room temperature for 20 min. Finally, 50 μl of stop solution was added to each well and mixed well by gentle tapping. The signal was measured using a microplate reader set to 450 nm, 570, and 540 nm. Perform wavelength correction by subtracting readings at 540 nm or 570 nm from the readings at 450 nm.</p></sec><sec id="s4-15"><title>Antibodies</title><sec id="s4-15-1"><title>Primary antibodies</title><list list-type="simple"><list-item><p>TRF2 rabbit polyclonal (Novus NB110-57130)- ChIP, IP, WB.</p></list-item><list-item><p>TRF2 mouse monoclonal (Millipore 4A794)- Flow cytometry.</p></list-item><list-item><p>TRF1 mouse monoclonal (Novus NB110-68281)- WB.</p></list-item><list-item><p>IL1R1 rabbit polyclonal (abcam ab106278)- IF, Flow-Cytometry, WB.</p></list-item><list-item><p>DDK/FLAG mouse monoclonal (Sigma-F1804)- ChIP, WB</p></list-item><list-item><p>BG4 recombinant antibody (Sigma Aldrich MABE917)- ChIP.</p></list-item><list-item><p>P300 (CST D2X6 N) rabbit monoclonal- ChIP, IF, WB.</p></list-item><list-item><p>Ac-p300/CBP (CST 4771) rabbit monoclonal- ChIP, WB.</p></list-item><list-item><p>CBP (CST 7389) rabbit monoclonal- ChIP, WB.</p></list-item><list-item><p>P65(NFKB) (CST 8242) rabbit monoclonal- WB.</p></list-item><list-item><p>Ser536 P p65 NFKB (CST 3033) rabbit monoclonal- WB</p></list-item><list-item><p>IKB (CST 4814) mouse monoclonal- WB.</p></list-item><list-item><p>p-IKB (CST 2589) rabbit monoclonal- WB.</p></list-item><list-item><p>CD44 (CST 3570) mouse monoclonal- IF.</p></list-item><list-item><p>Histone H3 rabbit polyclonal (Abcam ab1791)- ChIP.</p></list-item><list-item><p>H3K27ac rabbit polyclonal (Abcam ab4729)- ChIP.</p></list-item><list-item><p>H3K4me3 rabbit polyclonal (Abcam ab8580)- ChIP.</p></list-item><list-item><p>H3K27me3 rabbit monoclonal (abcam ab192985)- ChIP.</p></list-item><list-item><p>H3K9me3 rabbit polyclonal (abcam ab8898)- ChIP.</p></list-item><list-item><p>Beta-actin mouse monoclonal (Santacruz C4)- WB.</p></list-item><list-item><p>GAPDH mouse monoclonal (Santacruz 6C5)- WB.</p></list-item><list-item><p>CD11b Monoclonal Antibody (ICRF44), eBioscience- Flow cytometry.</p></list-item><list-item><p>CD206 Monoclonal Antibody (MR5D3) Invitrogen- Flow cytometry.</p></list-item><list-item><p>APC anti-human CD326 (EpCAM) (9C4) BioLegend- Flow cytometry.</p></list-item><list-item><p>FITC anti-human CD11B (ICRF44) BioLegend- Flow cytometry.</p></list-item><list-item><p>PE anti-human CD45 (HI30) BioLegend- Flow cytometry.</p></list-item><list-item><p>PE-Cy7 anti-human CD45 (W17233E) BioLegend- Flow cytometry.</p></list-item><list-item><p>Anti-Rabbit IgG/Anti-mouse IgG (Millipore) was used for isotype control.</p></list-item></list></sec><sec id="s4-15-2"><title>Secondary antibodies</title><p>Anti-Rabbit-HRP(CST), anti-Mouse-HRP(CST), mouse-ALP (Sigma), rabbit-ALP (Sigma), anti-rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 594 (Molecular Probes, Life Technologies).</p></sec></sec><sec id="s4-16"><title>Real-time PCR</title><p>Total RNA was isolated from cells using TRIzol Reagent (Invitrogen, Life Technologies) according to manufacturer’s instructions. For TNBC tissue and xenograft, Allprep DNA/RNA Universal kit from QIAGEN was used. The cDNA was prepared using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using manufacturer provided protocol. A relative transcript expression level for genes was measured by quantitative real-time PCR using a SYBR Green (Takara) based method. Gene expression was calculated as 2<sup>-delCT</sup> with delCT being the difference in threshold cycles (Ct) between test and internal control. <italic>GAPDH</italic> / 18 S gene was used as internal control for normalizing the cDNA concentration of each sample. For fold change of gene expression calculations, 2<sup>-delCT</sup> for the first replicate of the control sample was used for normalisation for the samples. Normalised expression values (fold change) were plotted and compared with appropriate statistical testing.</p><p>RT PCR primers used have been enlisted as follows:</p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2">mRNA expression primers</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>IL1R1FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCTGAAAAGCATAGAGGGAAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CTGGGCTCACAATCACAGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TRF2 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGTGTCTGTCGCGGATTGAA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TRF2 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CATTGATAGCTGATTCCAGTGGT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1B FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGATGGCTTATTACAGTGGCAA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1B RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GTCGGAGATTCGTAGCTGGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1A FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGATGCCTGAGATACCCAAAACC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1A RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAAGCACACCCAGTAGTCT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL2 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CATTTGTGGTTGGGTCAGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL2 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGTGAGGAACAAGCCAGAGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL6 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCACTCCTTGGCAAAACTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL6 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CGGAAGGAACCATCTCACTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TNF FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GCCAGAGGGCTGATTAGAGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TNF RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCAGCCTCTTCTCCTTCCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL8 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GAATGGGTTTGCTAGAATGTGATA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL8 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGACTAGGGTTGCCAGATTTAAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL10 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GACTTTAAGGGTTACCTGGGTTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL10 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCACATGCGCCTTGATGTCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL4 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAACTGCTTCCCCCTCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL4 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTGTTACGGTCAACTCGGTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL13 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GAAGGCTCCGCTCTGCAAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL13 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCAGGGCTGCACAGTACA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>GAPDH FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGCACCACCAACTGCTTAGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>GAPDH RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GGCATGGACTGTGGTCATGAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>18 S FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TTCGGAACTGAGGCCATGAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>18 S RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TTTCGCTCTGGTCCGTCTTG</named-content></td></tr></tbody></table></table-wrap><p>TRF2 target gene expression primers from <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>.</p></sec><sec id="s4-17"><title>RNA-seq analysis</title><p>RNA was extracted using TRIzol TruSeq RNA Library Prep Kit v2 was used from preparation of libraries for sequencing. Raw Illumina sequencing reads were checked for quality using FastQC (version 0.11.9) followed by adapter clipping and trimming using Trimmomatic (version 0.39) with default parameters. Trimmed reads were then aligned to the human reference genome (GRCh38, GENCODE v36) using STAR aligner (version 2.7.8 a; <xref ref-type="bibr" rid="bib26">Dobin et al., 2013</xref>). FeatureCounts (subread package version 2.0.1) was used to quantify gene expression (<xref ref-type="bibr" rid="bib76">Quinlan and Hall, 2010</xref>). Quality checks were performed at each step using the MultiQC tool (version 1.10.1). Differential gene expression analysis was performed using the DESseq2 package (version 1.30.0; <xref ref-type="bibr" rid="bib58">Love et al., 2016</xref>) in R (version 4.0.3). The analysis was performed by removing the effects of confounding variables such as batch and replicate using the appropriate design formula. Gene expression was normalised using variant stabilizing transformation (vst) for visualisation purposes. Genes with BH-adjusted p-value &lt;0.05 and absolute Log2 fold change greater than 1 (at least 100% fold change in either direction) were taken as significantly differentially expressed. Two replicates for each sample were used for differential gene expression analysis.</p></sec><sec id="s4-18"><title>ChIP (chromatin immunoprecipitation)</title><p>ChIP assays were performed as as previously reported by <xref ref-type="bibr" rid="bib67">Mukherjee et al., 2019a</xref>; <xref ref-type="bibr" rid="bib68">Mukherjee et al., 2019b</xref>; <xref ref-type="bibr" rid="bib66">Mukherjee et al., 2018</xref>. Briefly, 3–5 million cells were fixed with ~1% formaldehyde (Sigma-Aldrich) for 10 min and lysed. Chromatin was sheared to an average size of ∼300–400 bp using Biorupter (Diagenode). 10% of the sonicated fraction was processed as input using phenol–chloroform and ethanol precipitation. ChIP was performed for endogenous/ectopically expressed protein using 1:100 dilution (v/v) of the respective ChIP grade antibody incubated overnight at 4 °C. Immune complexes were collected using Salmon sperm DNA-saturated Magnetic Dynabeads (–50 μg per sample) and washed extensively. Phenol-chloroform-isoamylalcohol was used to extract DNA from the immunoprecipitated fraction. ChIP DNA was quantified by Qubit HS ds DNA kit (Thermo Fisher Scientific). Quantified ChIP samples were validated by qRT-PCR.</p><p>ChIP enrichment was calculated over 1% input as: 2<sup>-(CT ChIP-CT 1% input)</sup>. Following this, the ChIP enrichment was normalised to enrichment value for respective IgG (Mock) or total H3 ChIP.</p><p>The ChIP-qRT PCR primers are as follows:</p><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2">ChIP- qRT PCR primers</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>IL1R1-1000 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCCTTCCACAGAAGAAACCTGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-1000 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CGCAGAAGCCAGTGGGAGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-800 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCCCAGGTGGGTGCCA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-800 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGACAGAATGATTCTTTGCTCTGTGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-600 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TATTTGTCAGGCGCCCCTGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-600 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CATACATCTGTGTGTGCCTGGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-400 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGAAGCCATACATCTGTGTAGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-400 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GAATGTTATACACACACTCATACACACACACA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-200 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GAGTGTGTGTATAACATTCATTACTGCAAAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1-200 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGAAAAGATACAAGTGAAGAGCTGCC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1+200 FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TGGGAGGTGACACCCAGTTTAAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1+200 RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAACTCTGGGCCTTCCCAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1 3' UTR FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTTTGACTTATTGTCCCCACT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1 3' UTR RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTTCAACACTTAGGGCATCTT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1 –20 KB FP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TTGTCCTGAATAGCCGCAGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IL1R1 –20 KB RP</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCTCGAGAAAACAGCCCAT</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-19"><title>Immunofluorescence microscopy</title><p>Adherent cells were seeded on coverslips and allowed to reach a confluency of ~70%. Cells were fixed using freshly prepared 4% Paraformaldehyde by incubating for 10 min at RT. Cells were permeabilised with 0.25% Triton X-100 (10 min at RT) and treated with blocking solution (5% BSA in PBS) for 2 hr at RT. All the above stated were followed by three washes with ice cold PBS for 5 min each. Post-blocking, cells treated with relevant antibodies (1:500 for TRF2, 1:500 for IL1R1 and 1:1000 for CD44/p300) and incubated overnight at 4 °C in a humid chamber. Post-incubation, cells were washed alternately with PBS and PBST three times and probed with secondary Ab (rabbit Alexa Fluor 488 (1:1000) / mouse Alexa Fluor 594 (1:1000)) for 2 hr at RT. Cells were washed again alternately with PBS and PBST three times and mounted with Prolong Gold anti-fade reagent with DAPI. Images were taken on Leica TCS-SP8 confocal microscope/ Cytiva Deltavision microscope. Lasers of emission wavelength 405 nm, 488 nm and 532 nm were used imaging for DAPI, Alexa Fluor 488 secondary Ab and Alexa Fluor 594 Ab respectively. Laser intensity was kept 20% for DAPI and 40–60% for Alexa Fluor secondary antibodies. ImageJ (FIJI) software was used to calculate signal intensity (a.u.).</p></sec><sec id="s4-20"><title>Western blotting</title><p>For western blot analysis, protein lysates were prepared by suspending cell pellets in 1 X RIPA (with 1 x mammalian protease inhibitor cocktail). Protein was separated using 10%/12% SDS-PAGE and transferred to polyvinylidenedifluoride membranes (Immobilon FL, Millipore). After blocking, the membrane was incubated with primary antibodies. Post incubation with primary antibodies (1:1000 v/v), the membrane was washed with 1 X PBS and then incubated with appropriate secondary antibodies (1:2000 v/v). Following secondary antibody incubation, the membrane was washed with 1XPBS. The blot was finally developed using HRP substrate/BCP NBT and reagents from Millipore.</p></sec><sec id="s4-21"><title>HT1080 TRF2 and TERT inducible cells</title><p>TRF2 cDNA sequence was inserted into pENTR11 vector and the cassette was transferred into lentiviral plasmid pCW57.1 by gateway cloning. Following this viral particles were generated from HEK293T cells and the viral soup with polybrene (Sigma-Aldrich) was used for transduction. Cells with insert were selected with 1 μg/ml of puromycin and tested for TRF2 induction using varying doxycycline concentrations.</p><p>Similarly TERT cDNA was amplified from a mammalian expression vector and inserted into pENTR11 vector. Subsequently, the same strategy was used to generate and test TERT inducible HT1080 cells.</p></sec><sec id="s4-22"><title>Vector constructs</title><p>The pCMV6-myc-DDK(FLAG)-TRF2 vector (TRF2 WT) was procured from Origene (RC223601). The mutants delB and delM constructs used in the study have been previously reported (<xref ref-type="bibr" rid="bib42">Hussain et al., 2017</xref>) and made through mutagenesis of the TRF2 WT construct. TRF2 shRNA was procured from Origene (TL308880). Side-directed Mutagenesis was performed on the TRF2 WT plasmid to generate the PTM mutants.</p><p>For customizing dCas9-TRF2 fusion plasmids, the backbone of dCAS9-VP64-GFP (Addgene 61422) was used. IL1R1 sgRNA was custom designed against IL1R1 promoter G-quadruplex (G4-motif B) and cloned in pX333 (Addgene 64073) backbone after replacing Cas9 with mCherry.</p></sec><sec id="s4-23"><title>Transfections</title><p>TRF2 wildtype (myc/DDK tag) or mutant mammalian expression vector pCMV6 was transfected into HT1080 /MDAMB231 cells that were 60% confluent using Lipofectamine 2000 transfection reagent (following the manufacturers’ protocol). 2–4 μg of plasmid was used for transfection in a 35 mm well for each case.</p><p>In case of TRF2 shRNA (Origene)/TERC shRNA (Santa Cruz Biotechnology), 4 μg of plasmid was used for transfection in a 35 mm well for each case and Fugene HD transfection reagent was used as per manufacturer’s protocol. Cells were then maintained in 1 μg/ml of puromycin for stable shRNA maintenance. For dCAS9-TRF2 fusion constructs, co-transfected with IL1R1 sgRNA plasmid, FugeneHD was used at recommended concentrations.</p></sec><sec id="s4-24"><title>TRF2 silencing by siRNA</title><p>HT1080 cells were transfected with TRF2 siRNA oligonucleotides (synthesised from Eurogenetics Pvt. Limited; <xref ref-type="bibr" rid="bib88">Sharma et al., 2021</xref>) using lipofectamine 2000 (Invitrogen) transfection reagent according to manufacturer’s instructions. Silencing was checked after 48 hr of transfection. Pooled scrambled siRNA was used as control.</p></sec><sec id="s4-25"><title>Luciferase assay</title><p>IL1R1 promoter (upto 1500 bp upstream of transcription start site) was cloned in PGL3 basic vector upstream of firefly luciferase construct. G4 motif disrupting mutations were introduced in the promoter construct by site directed mutagenesis.</p><p>Plasmid (pGL4.73) containing a SV-40 promoter driving Renilla luciferase was co-transfected as transfection control for normalisation. After 48 hr, cells were harvested and luciferase activities of cell lysate were recorded by using a dual-luciferase reporter assay system (Promega).</p></sec><sec id="s4-26"><title>Circular dichroism</title><p>Circular Dichroism (CD) profiles (220 nm to 300 nm) were obtained for representative G4 motifs identified within IL1R1 promoter and an overlap with TRF2 high confidence ChIP seqpeak. CD showed the formation of G4-motif with the unaltered sequence while mutated G4 sequence gave partial/complete disruption of the G4-motif under similar conditions (buffer used for G- quadruplex formation –10 mM Na cacodylate and 100 mM KCl). The CD spectra were recorded on a Jasco-89spectropolarimeter equipped with a Peltier temperature controller. Experiments were carried out using a 1 mm path-length cuvette over a wavelength range of 200–320 nm. Oligonucleotides were synthesised commercially from Sigma-Aldrich. 2.5 µM oligonucleotides were diluted in sodium cacodylate buffer (10 mM sodium cacodylate and 100 mM KCl, pH 7.4) and denatured by heating to 95 °C for 5 min and slowly cooled to 15 °C for several hours. The CD spectra reported here are representations of three averaged scans taken at 20 °C and are baseline corrected for signal contributions due to the buffer.</p></sec><sec id="s4-27"><title>CCR5-IL1R1 promoter insert cells</title><p>IL1R1 promoter and downstream firefly luciferase (and G4 mutant variant) was inserted in HEK293T cells by using strategy previously standardised and reported for TERT promoter-gaussia insertion in the same locus (<xref ref-type="bibr" rid="bib88">Sharma et al., 2021</xref>).</p></sec><sec id="s4-28"><title>IL1R1 promoter G4 mutant HEK cells</title><p>Custom designed gRNA pair was used to insert mutant G4 template sequence (G4 mutantB) into the IL1R1 endogenous promoter by co-transfecting Cas9and gRNA pair with doner template SSODN sequence. Following this, single cell screen was done for positive mutant colony. Once identified an appropriate mutant colony was used for experiments.</p><p>sgRNA and SSODN details are as follows:</p><p>sgRNA1- 5’- <named-content content-type="sequence">GCTGCCAATGGGT<bold>G</bold><underline>GAGTC</underline>TTG<bold>G</bold>G</named-content> –3’ (efficiency score (Doench et al)- 35)</p><p>-ve strand, ssODN: 91 bp (PAM proximal)- 36 bp (PAM distal)</p><p>Target strand is +ve strand. Non-target stand is –ve strand. ssODN should be +ve strand.</p><p><bold>ssODN</bold> (mutated): chr2:102070276–102070402</p><p><named-content content-type="sequence">GGGACACTGCAGCCCTGGCCTGGCCTACTTTTCTCTTCTCCCATATCTGGAAAATGAAAGTAGCCTGACGTATCCGGGGACACGGCACAAGACTCAACCCATTGGCAGCTCTTCACTTGTATCTTTT</named-content></p><p>sgRNA2- 5’- <named-content content-type="sequence">GCAATGGGT<bold>G</bold><underline>GAGTC</underline>TTG<bold>G</bold>GCCG<bold>G</bold></named-content> –3’ (efficiency score (Doench et al)- 40)</p><p>-ve strand, ssODN: 85 bp (PAM proximal)- 42 bp (PAM distal).</p></sec><sec id="s4-29"><title>Immunoprecipitation</title><p>Immunoprecipitation of proteins was performed using modified version of suggested IP protocol from CST. Cells were lysed using cell lysis buffer ((1 X) 20 mM Tris (pH 7.5), 150 mM NaCl (Sigma-Aldrich), 1 mM EDTA (Sigma-Aldrich), 1 mM EGTA (Sigma-Aldrich), 1% Triton X-100 (Sigma-Aldrich), 2 X mPIC (Thermo Fisher Scientific)) and treated with relevant primary antibody (1: 100 v/v) overnight at 4 °C or mock IgG on rotor. 50 µg of Dyanbeads (blocked with BSA-5% for 60 mins at RT) was added to the lysis soup and kept for 2 hr in mild agitation. Dynabeads were magnetically separated and washed thrice (with 1 X PBS with 0.1% Tween-20). The beads were resuspended with 1 X RIPA (50 µl) and 1 X Laemmli buffer. This was followed by denaturation at 95°Cfor 10 min and followed by western blot for specific proteins.</p></sec><sec id="s4-30"><title>HAT assay</title><p>Histone acetyl transferase (HAT) assay was performed as per manufacturers’ protocol from Active motif. Mammalian TRF2 and p300 full length were commercially procured from Origene and Abcam respectively and used for the assay.</p></sec><sec id="s4-31"><title>IL1R1 knockout HT1080 cells</title><p>Two sets of gRNAs targeting either exon 3 or exon3-7 of <italic>IL1R1</italic> coding region were cloned in PX459 (Addgene 62988) and co-transfected in HT1080 cells, followed by puromycin selection and single cell screening for IL1R1 knockout cells. A knockout clone was selected (based on IL1R1 depletion) and used for further experiments.</p></sec><sec id="s4-32"><title>Gene ontology and cBIO PORTAL analysis</title><p>Gene Ontology for KEGG pathway enrichment and associated figures were generated using ShinyGO web portal (<xref ref-type="bibr" rid="bib28">Ge et al., 2020</xref>). Gene ontology (Biological Process) analysis was done using gene list (<xref ref-type="bibr" rid="bib6">Barthel et al., 2017</xref>) using publicly available resource –The Gene Ontology Resource database (<ext-link ext-link-type="uri" xlink:href="http://geneontology.org/">http://geneontology.org/</ext-link>). Fold enrichment, FDR values and p-values were calculated using PANTHER. Ontology plot was made using MS Excel multivariate plot. <italic>IL1R1</italic> high/low samples were segregated, and differential gene expression gene list was generated using cBioPortal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>) using the TCGA Breast Invasive carcinoma dataset (Firehose legacy). Sample IDs for the patient samples have been provided in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. For <italic>IL1R1</italic> high samples, the cut-off used was 1.5 times the standard deviation of the mean expression value. Custom query commands were used to fetch the <italic>IL1R1</italic> high and low sample IDs. DEG list and survival plots were generated using in-built functions of cBioPortal.</p></sec><sec id="s4-33"><title>TRAP (telomere repeat amplification protocol) for telomerase activity</title><p>Protein lysate was prepared in 1 X CHAPS Lysis Buffer and the assay was performed using TRAPeze RT Telomerase Detection Kit (Merck) per manufacturer’s instructions.</p></sec><sec id="s4-34"><title>Statistical analysis</title><p>All statistical tests were performed using interface provided within GRAPHPAD PRISM software. Median values and correlations were calculated using MS excel functions.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con15"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con16"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con17"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con18"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con19"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con20"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con21"><p>Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human TNBC tissue samples were procured after due institutional ethics committee clearance as follows: 1. Rajiv Gandhi Cancer Centre and Research Institute-Delhi, India - RGCIRC/IRB/119/2020 clearance for project awarded to Dr. Ankita Singh and Dr. Shantanu Chowdhury under the project titled- &quot;molecular mechanisms of how telomeres impact global gene expression : potential role of TRF2 in telomere-chromatin interactions&quot;, 2. CSIR-Institute of Genomics and Integrative Biology-Delhi, India - Human ethics committee clearance awarded to Dr. Shantanu Chowdhury (CSIR-IGIB/IHEC/20219-20/dt. 04.02.2020) for the project titled- &quot;molecular mechanisms of how telomeres impact global gene expression : potential role of TRF2 in telomere-chromatin interactions&quot;. All committee guidelines were followed for the procurement and experiments with fixed TNBC tissue samples. All informed content from patients was obtained following committee recommendations.</p></fn><fn fn-type="other"><p>The animal experiments were performed in accordance with guidelines and recommendations laid out by the institutional animal ethics committee (IAEC) at CSIR-Institute of Genomics and Integrative Biology-Delhi, India after due clearance was awarded to Dr. Shantanu Chowdhury (IGIB/IAEC/11/28/2020).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95106-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>DEG list (upregulated and downregulated) for long vs short telomere HT1080 fibrosarcoma cells.</title></caption><media xlink:href="elife-95106-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Immune related TRF2 ChIP-seq target genes.</title></caption><media xlink:href="elife-95106-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>RTL for TNBC samples (normalized to HT1080).</title></caption><media xlink:href="elife-95106-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>TCGA sample list for IL1R1 high vs low BRCA analysis.</title></caption><media xlink:href="elife-95106-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Relative expression and correlation of key immune marker genes in BRCA patient sample data curated from TCGA.</title></caption><media xlink:href="elife-95106-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The authors declare that all data necessary to support the inferences are included in the manuscript and supplementary files. Source data has been provided for all figures and figure supplements. Additionally, raw data for the RNA sequencing (HT1080-HT1080-LT cells) has been made public (GEO accession code GSE267781).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Faruq</surname><given-names>M</given-names></name><name><surname>Budharaja</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Transcriptional outcome of telomere elongation in human fibrosarcoma model</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267781">GSE267781</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge Manish Rai (confocal imaging), Debojyoti Chakraborty Lab (DeltaVision Microscopy), Vivek Rao (THP1 cells) and Mohit Agarwal (ELISA experiments) from CSIR-IGIB. Fellowships from CSIR (AKM, AS, SSR, SS, ASG, SVM, SB and DS); DBT-Wellcome Trust India Alliance (AKM, AS, MC, MV and AP); UGC (SD) and DST (DK) are acknowledged. RS and NG acknowledges intramural funding support from NCBS-TIFR. This work was supported by the DBT/Wellcome Trust India Alliance Fellowship [grant number IA/S/18/2/504021] awarded to SC, and research funding from the Council of Scientific and Industrial Research (CSIR), Ashoka University and Department of Biotechnology (DBT).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Solinas</surname><given-names>G</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages</article-title><source>Critical Reviews in Oncology/Hematology</source><volume>66</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2007.07.004</pub-id><pub-id pub-id-type="pmid">17913510</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arango Duque</surname><given-names>G</given-names></name><name><surname>Descoteaux</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Macrophage cytokines: involvement in immunity and infectious diseases</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>491</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00491</pub-id><pub-id pub-id-type="pmid">25339958</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artandi</surname><given-names>SEE</given-names></name><name><surname>DePinho</surname><given-names>RAA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Telomeres and telomerase in cancer</article-title><source>Carcinogenesis</source><volume>31</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp268</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutations, cancer and the telomere length paradox</article-title><source>Trends in Cancer</source><volume>3</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.02.005</pub-id><pub-id pub-id-type="pmid">28718437</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Inflammation and cancer: Back to Virchow?</article-title><source>The Lancet</source><volume>357</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthel</surname><given-names>FPP</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Martinez-Ledesma</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Amin</surname><given-names>SBB</given-names></name><name><surname>Akdemir</surname><given-names>KCC</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lichtenberg</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Verhaak</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systematic analysis of telomere length and somatic alterations in 31 cancer types</article-title><source>Nature Genetics</source><volume>49</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/ng.3781</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>JA</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Telomere position effect in human cells</article-title><source>Science</source><volume>292</volume><fpage>2075</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1126/science.1062329</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Tannahill</surname><given-names>D</given-names></name><name><surname>McCafferty</surname><given-names>J</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Quantitative visualization of DNA G-quadruplex structures in human cells</article-title><source>Nature Chemistry</source><volume>5</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nchem.1548</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>EW</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Fearon</surname><given-names>DF</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Howcroft</surname><given-names>TK</given-names></name><name><surname>Woodhouse</surname><given-names>EC</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nature Medicine</source><volume>24</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0014-x</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biroccio</surname><given-names>A</given-names></name><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Augereau</surname><given-names>A</given-names></name><name><surname>Pinte</surname><given-names>S</given-names></name><name><surname>Bauwens</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Simonet</surname><given-names>T</given-names></name><name><surname>Horard</surname><given-names>B</given-names></name><name><surname>Jamet</surname><given-names>K</given-names></name><name><surname>Cervera</surname><given-names>L</given-names></name><name><surname>Mendez-Bermudez</surname><given-names>A</given-names></name><name><surname>Poncet</surname><given-names>D</given-names></name><name><surname>Grataroli</surname><given-names>R</given-names></name><name><surname>de Rodenbeeke</surname><given-names>CT</given-names></name><name><surname>Salvati</surname><given-names>E</given-names></name><name><surname>Rizzo</surname><given-names>A</given-names></name><name><surname>Zizza</surname><given-names>P</given-names></name><name><surname>Ricoul</surname><given-names>M</given-names></name><name><surname>Cognet</surname><given-names>C</given-names></name><name><surname>Kuilman</surname><given-names>T</given-names></name><name><surname>Duret</surname><given-names>H</given-names></name><name><surname>Lépinasse</surname><given-names>F</given-names></name><name><surname>Marvel</surname><given-names>J</given-names></name><name><surname>Verhoeyen</surname><given-names>E</given-names></name><name><surname>Cosset</surname><given-names>F-L</given-names></name><name><surname>Peeper</surname><given-names>D</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Londoño-Vallejo</surname><given-names>A</given-names></name><name><surname>Sabatier</surname><given-names>L</given-names></name><name><surname>Picco</surname><given-names>V</given-names></name><name><surname>Pages</surname><given-names>G</given-names></name><name><surname>Scoazec</surname><given-names>J-Y</given-names></name><name><surname>Stoppacciaro</surname><given-names>A</given-names></name><name><surname>Leonetti</surname><given-names>C</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Gilson</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>818</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/ncb2774</pub-id><pub-id pub-id-type="pmid">23792691</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Telomere states and cell fates</article-title><source>Nature</source><volume>408</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/35040500</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briukhovetska</surname><given-names>D</given-names></name><name><surname>Dörr</surname><given-names>J</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Kobold</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Interleukins in cancer: From biology to therapy</article-title><source>Nature Reviews. Cancer</source><volume>21</volume><fpage>481</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00363-z</pub-id><pub-id pub-id-type="pmid">34083781</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkholder</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Burgess</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>VS</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>ZQ</given-names></name><name><surname>Gao</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>BL</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Huang</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor-induced perturbations of cytokines and immune cell networks</article-title><source>Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1845</volume><fpage>182</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2014.01.004</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmi</surname><given-names>Y</given-names></name><name><surname>Voronov</surname><given-names>E</given-names></name><name><surname>Dotan</surname><given-names>S</given-names></name><name><surname>Lahat</surname><given-names>N</given-names></name><name><surname>Rahat</surname><given-names>MA</given-names></name><name><surname>Fogel</surname><given-names>M</given-names></name><name><surname>Huszar</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Apte</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis</article-title><source>Journal of Immunology</source><volume>183</volume><fpage>4705</fpage><lpage>4714</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901511</pub-id><pub-id pub-id-type="pmid">19752225</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassetta</surname><given-names>L</given-names></name><name><surname>Noy</surname><given-names>R</given-names></name><name><surname>Swierczak</surname><given-names>A</given-names></name><name><surname>Sugano</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>H</given-names></name><name><surname>Wiechmann</surname><given-names>L</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Isolation of mouse and human tumor-associated macrophages</article-title><source>Advances in Experimental Medicine and Biology</source><volume>899</volume><fpage>211</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-26666-4_12</pub-id><pub-id pub-id-type="pmid">27325269</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanmee</surname><given-names>T</given-names></name><name><surname>Ontong</surname><given-names>P</given-names></name><name><surname>Konno</surname><given-names>K</given-names></name><name><surname>Itano</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor-associated macrophages as major players in the tumor microenvironment</article-title><source>Cancers</source><volume>6</volume><fpage>1670</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.3390/cancers6031670</pub-id><pub-id pub-id-type="pmid">25125485</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JJW</given-names></name><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Yao</surname><given-names>P-L</given-names></name><name><surname>Yuan</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Shun</surname><given-names>C-T</given-names></name><name><surname>Tsai</surname><given-names>M-F</given-names></name><name><surname>Chen</surname><given-names>C-H</given-names></name><name><surname>Yang</surname><given-names>P-C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Tumor-associated macrophages: the double-edged sword in cancer progression</article-title><source>Journal of Clinical Oncology</source><volume>23</volume><fpage>953</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.12.172</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Giotti</surname><given-names>B</given-names></name><name><surname>Kaluzova</surname><given-names>M</given-names></name><name><surname>Vallcorba</surname><given-names>MP</given-names></name><name><surname>Rawat</surname><given-names>K</given-names></name><name><surname>Price</surname><given-names>G</given-names></name><name><surname>Herting</surname><given-names>CJ</given-names></name><name><surname>Pinero</surname><given-names>G</given-names></name><name><surname>Cristea</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>JL</given-names></name><name><surname>Ackley</surname><given-names>J</given-names></name><name><surname>Maximov</surname><given-names>V</given-names></name><name><surname>Szulzewsky</surname><given-names>F</given-names></name><name><surname>Thomason</surname><given-names>W</given-names></name><name><surname>Marquez-Ropero</surname><given-names>M</given-names></name><name><surname>Angione</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>N</given-names></name><name><surname>Tsankova</surname><given-names>NM</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Shayakhmetov</surname><given-names>DM</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Tsankov</surname><given-names>AM</given-names></name><name><surname>Hambardzumyan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression</article-title><source>The Journal of Clinical Investigation</source><volume>133</volume><elocation-id>e163802</elocation-id><pub-id pub-id-type="doi">10.1172/JCI163802</pub-id><pub-id pub-id-type="pmid">37733448</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Iltis</surname><given-names>C</given-names></name><name><surname>Cervera</surname><given-names>L</given-names></name><name><surname>Pisano</surname><given-names>S</given-names></name><name><surname>Croce</surname><given-names>O</given-names></name><name><surname>Sadouni</surname><given-names>N</given-names></name><name><surname>Győrffy</surname><given-names>B</given-names></name><name><surname>Collet</surname><given-names>R</given-names></name><name><surname>Renault</surname><given-names>VM</given-names></name><name><surname>Rey-Millet</surname><given-names>M</given-names></name><name><surname>Leonetti</surname><given-names>C</given-names></name><name><surname>Zizza</surname><given-names>P</given-names></name><name><surname>Allain</surname><given-names>F</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Soubeiran</surname><given-names>N</given-names></name><name><surname>Shkreli</surname><given-names>M</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Biroccio</surname><given-names>A</given-names></name><name><surname>Gilson</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e100012</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018100012</pub-id><pub-id pub-id-type="pmid">31000523</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>V</given-names></name><name><surname>Toh</surname><given-names>HC</given-names></name><name><surname>Abastado</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immune microenvironment in tumor progression: Characteristics and challenges for therapy</article-title><source>Journal of Oncology</source><volume>2012</volume><elocation-id>608406</elocation-id><pub-id pub-id-type="doi">10.1155/2012/608406</pub-id><pub-id pub-id-type="pmid">22927846</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chittezhath</surname><given-names>M</given-names></name><name><surname>Dhillon</surname><given-names>MK</given-names></name><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>Laoui</surname><given-names>D</given-names></name><name><surname>Shalova</surname><given-names>IN</given-names></name><name><surname>Teo</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kamaraj</surname><given-names>R</given-names></name><name><surname>Raman</surname><given-names>L</given-names></name><name><surname>Lum</surname><given-names>J</given-names></name><name><surname>Thamboo</surname><given-names>TP</given-names></name><name><surname>Chiong</surname><given-names>E</given-names></name><name><surname>Zolezzi</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Van Ginderachter</surname><given-names>JA</given-names></name><name><surname>Poidinger</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>ASC</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression</article-title><source>Immunity</source><volume>41</volume><fpage>815</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.09.014</pub-id><pub-id pub-id-type="pmid">25453823</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristofari</surname><given-names>G</given-names></name><name><surname>Lingner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Telomere length homeostasis requires that telomerase levels are limiting</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600952</pub-id><pub-id pub-id-type="pmid">16424902</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubiles</surname><given-names>MD</given-names></name><name><surname>Barroso</surname><given-names>S</given-names></name><name><surname>Vaquero-Sedas</surname><given-names>MI</given-names></name><name><surname>Enguix</surname><given-names>A</given-names></name><name><surname>Aguilera</surname><given-names>A</given-names></name><name><surname>Vega-Palas</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Epigenetic features of human telomeres</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>2347</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1093/NAR/GKY006</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNardo</surname><given-names>DG</given-names></name><name><surname>Ruffell</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophages as regulators of tumour immunity and immunotherapy</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>369</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0127-6</pub-id><pub-id pub-id-type="pmid">30718830</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Estimating telomere length from whole genome sequence data</article-title><source>Nucleic Acids Research</source><volume>42</volume><elocation-id>e75</elocation-id><pub-id pub-id-type="doi">10.1093/NAR/GKU181</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: Ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/BIOINFORMATICS/BTS635</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Juhos</surname><given-names>S</given-names></name><name><surname>Larsson</surname><given-names>M</given-names></name><name><surname>Olason</surname><given-names>PI</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Eisfeldt</surname><given-names>J</given-names></name><name><surname>DiLorenzo</surname><given-names>S</given-names></name><name><surname>Sandgren</surname><given-names>J</given-names></name><name><surname>Díaz De Ståhl</surname><given-names>T</given-names></name><name><surname>Ewels</surname><given-names>P</given-names></name><name><surname>Wirta</surname><given-names>V</given-names></name><name><surname>Nistér</surname><given-names>M</given-names></name><name><surname>Käller</surname><given-names>M</given-names></name><name><surname>Nystedt</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants</article-title><source>F1000Research</source><volume>9</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.16665.2</pub-id><pub-id pub-id-type="pmid">32269765</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>SX</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ShinyGO: A graphical gene-set enrichment tool for animals and plants</article-title><source>Bioinformatics</source><volume>36</volume><fpage>2628</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz931</pub-id><pub-id pub-id-type="pmid">31882993</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Saginc</surname><given-names>G</given-names></name><name><surname>Leow</surname><given-names>SC</given-names></name><name><surname>Khattar</surname><given-names>E</given-names></name><name><surname>Shin</surname><given-names>EM</given-names></name><name><surname>Yan</surname><given-names>TD</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chng</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Tergaonkar</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Telomerase directly regulates NF-κB-dependent transcription</article-title><source>Nature Cell Biology</source><volume>14</volume><fpage>1270</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/ncb2621</pub-id><pub-id pub-id-type="pmid">23159929</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>H</given-names></name><name><surname>Hagerling</surname><given-names>C</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Roles of the immune system in cancer: From tumor initiation to metastatic progression</article-title><source>Genes &amp; Development</source><volume>32</volume><fpage>1267</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1101/gad.314617.118</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goronzy</surname><given-names>JJ</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Telomeres, immune aging and autoimmunity</article-title><source>Experimental Gerontology</source><volume>41</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2005.12.002</pub-id><pub-id pub-id-type="pmid">16427234</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granotier</surname><given-names>C</given-names></name><name><surname>Pennarun</surname><given-names>G</given-names></name><name><surname>Riou</surname><given-names>L</given-names></name><name><surname>Hoffschir</surname><given-names>F</given-names></name><name><surname>Gauthier</surname><given-names>LR</given-names></name><name><surname>De Cian</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>D</given-names></name><name><surname>Mandine</surname><given-names>E</given-names></name><name><surname>Riou</surname><given-names>J-F</given-names></name><name><surname>Mergny</surname><given-names>J-L</given-names></name><name><surname>Mailliet</surname><given-names>P</given-names></name><name><surname>Dutrillaux</surname><given-names>B</given-names></name><name><surname>Boussin</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Preferential binding of a G-quadruplex ligand to human chromosome ends</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>4182</fpage><lpage>4190</lpage><pub-id pub-id-type="doi">10.1093/nar/gki722</pub-id><pub-id pub-id-type="pmid">16052031</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greider</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Telomerase activity, cell proliferation, and cancer</article-title><source>PNAS</source><volume>95</volume><fpage>90</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.1.90</pub-id><pub-id pub-id-type="pmid">9419332</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The hallmarks of cancer</article-title><source>Cell</source><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81683-9</pub-id><pub-id pub-id-type="pmid">10647931</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Her</surname><given-names>YR</given-names></name><name><surname>Chung</surname><given-names>IK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>p300-mediated acetylation of TRF2 is required for maintaining functional telomeres</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>2267</fpage><lpage>2283</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1354</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirashima</surname><given-names>K</given-names></name><name><surname>Migita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Muramatsu</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Seimiya</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Telomere length influences cancer cell differentiation in vivo</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>2988</fpage><lpage>2995</lpage><pub-id pub-id-type="doi">10.1128/MCB.00136-13</pub-id><pub-id pub-id-type="pmid">23716593</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodes</surname><given-names>RJ</given-names></name><name><surname>Hathcock</surname><given-names>KS</given-names></name><name><surname>Weng</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Telomeres in T and B cells</article-title><source>Nature Reviews. Immunology</source><volume>2</volume><fpage>699</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/nri890</pub-id><pub-id pub-id-type="pmid">12209138</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homey</surname><given-names>B</given-names></name><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Chemokines: agents for the immunotherapy of cancer?</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/nri748</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor-associated macrophages in cancers</article-title><source>Clinical &amp; Translational Oncology</source><volume>18</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1007/s12094-015-1373-0</pub-id><pub-id pub-id-type="pmid">26264497</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>NA</given-names></name><name><surname>Eiholzer</surname><given-names>RA</given-names></name><name><surname>Kirs</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Ward-Hartstonge</surname><given-names>K</given-names></name><name><surname>Wiles</surname><given-names>AK</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Taha</surname><given-names>A</given-names></name><name><surname>Royds</surname><given-names>JA</given-names></name><name><surname>Slatter</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma</article-title><source>Modern Pathology</source><volume>29</volume><fpage>212</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2015.156</pub-id><pub-id pub-id-type="pmid">26769142</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>T</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Purohit</surname><given-names>G</given-names></name><name><surname>Kar</surname><given-names>A</given-names></name><name><surname>Kishore Mukherjee</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Dhapola</surname><given-names>P</given-names></name><name><surname>Maji</surname><given-names>B</given-names></name><name><surname>Vedagopuram</surname><given-names>S</given-names></name><name><surname>Horikoshi</surname><given-names>NTN</given-names></name><name><surname>Horikoshi</surname><given-names>NTN</given-names></name><name><surname>Pandita</surname><given-names>RK</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Bajaj</surname><given-names>A</given-names></name><name><surname>Riou</surname><given-names>JFF</given-names></name><name><surname>Pandita</surname><given-names>TK</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcription regulation of CDKN1A (p21/CIP1/WAF1) by TRF2 is epigenetically controlled through the REST repressor complex</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>11541</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-11177-1</pub-id><pub-id pub-id-type="pmid">28912501</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>NG</given-names></name><name><surname>Ozdag</surname><given-names>H</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>p300/CBP and cancer</article-title><source>Oncogene</source><volume>23</volume><fpage>4225</fpage><lpage>4231</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207118</pub-id><pub-id pub-id-type="pmid">15156177</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JJL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Senescence: Back to telomeres</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>14</volume><elocation-id>196</elocation-id><pub-id pub-id-type="doi">10.1038/nrm3544</pub-id><pub-id pub-id-type="pmid">23463217</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayasingam</surname><given-names>SD</given-names></name><name><surname>Citartan</surname><given-names>M</given-names></name><name><surname>Thang</surname><given-names>TH</given-names></name><name><surname>Mat Zin</surname><given-names>AA</given-names></name><name><surname>Ang</surname><given-names>KC</given-names></name><name><surname>Ch’ng</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluating the polarization of tumor-associated macrophages Into M1 and M2 phenotypes in human cancer tissue: Technicalities and challenges in routine clinical practice</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>1512</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.01512</pub-id><pub-id pub-id-type="pmid">32039007</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaynes</surname><given-names>JM</given-names></name><name><surname>Sable</surname><given-names>R</given-names></name><name><surname>Ronzetti</surname><given-names>M</given-names></name><name><surname>Bautista</surname><given-names>W</given-names></name><name><surname>Knotts</surname><given-names>Z</given-names></name><name><surname>Abisoye-Ogunniyan</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Calvo</surname><given-names>R</given-names></name><name><surname>Dashnyam</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Guerin</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Ravichandran</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Talsania</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>V</given-names></name><name><surname>Ghebremedhin</surname><given-names>A</given-names></name><name><surname>Karanam</surname><given-names>B</given-names></name><name><surname>Bin Salam</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>R</given-names></name><name><surname>Odzorig</surname><given-names>T</given-names></name><name><surname>Aiken</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Zarif</surname><given-names>JC</given-names></name><name><surname>de Groot</surname><given-names>AE</given-names></name><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Simeonov</surname><given-names>A</given-names></name><name><surname>Pate</surname><given-names>N</given-names></name><name><surname>Abu-Asab</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Southall</surname><given-names>N</given-names></name><name><surname>Ock</surname><given-names>C-Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Lopez</surname><given-names>H</given-names></name><name><surname>Kozlov</surname><given-names>S</given-names></name><name><surname>de Val</surname><given-names>N</given-names></name><name><surname>Yates</surname><given-names>CC</given-names></name><name><surname>Baljinnyam</surname><given-names>B</given-names></name><name><surname>Marugan</surname><given-names>J</given-names></name><name><surname>Rudloff</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>6337</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aax6337</pub-id><pub-id pub-id-type="pmid">32051227</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Nam</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone</article-title><source>Chemico-Biological Interactions</source><volume>258</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2016.08.021</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>I</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Shin</surname><given-names>HC</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer</article-title><source>Journal of Breast Cancer</source><volume>22</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.4048/jbc.2019.22.e5</pub-id><pub-id pub-id-type="pmid">30941232</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jochems</surname><given-names>C</given-names></name><name><surname>Schlom</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity</article-title><source>Experimental Biology and Medicine</source><volume>236</volume><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1258/ebm.2011.011007</pub-id><pub-id pub-id-type="pmid">21486861</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplanov</surname><given-names>I</given-names></name><name><surname>Carmi</surname><given-names>Y</given-names></name><name><surname>Kornetsky</surname><given-names>R</given-names></name><name><surname>Shemesh</surname><given-names>A</given-names></name><name><surname>Shurin</surname><given-names>GV</given-names></name><name><surname>Shurin</surname><given-names>MR</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Voronov</surname><given-names>E</given-names></name><name><surname>Apte</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation</article-title><source>PNAS</source><volume>116</volume><fpage>1361</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1073/pnas.1812266115</pub-id><pub-id pub-id-type="pmid">30545915</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlseder</surname><given-names>J</given-names></name><name><surname>Smogorzewska</surname><given-names>A</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Senescence induced by altered telomere state, not telomere loss</article-title><source>Science</source><volume>295</volume><fpage>2446</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.1126/science.1069523</pub-id><pub-id pub-id-type="pmid">11923537</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Ludlow</surname><given-names>AT</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Robin</surname><given-names>JD</given-names></name><name><surname>Stadler</surname><given-names>G</given-names></name><name><surname>Mender</surname><given-names>I</given-names></name><name><surname>Lai</surname><given-names>TP</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of the human telomerase gene TERT by Telomere Position Effect-Over Long Distances (TPE-OLD): implications for aging and cancer</article-title><source>PLOS Biology</source><volume>14</volume><elocation-id>e2000016</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2000016</pub-id><pub-id pub-id-type="pmid">27977688</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lappano</surname><given-names>R</given-names></name><name><surname>Talia</surname><given-names>M</given-names></name><name><surname>Cirillo</surname><given-names>F</given-names></name><name><surname>Rigiracciolo</surname><given-names>DC</given-names></name><name><surname>Scordamaglia</surname><given-names>D</given-names></name><name><surname>Guzzi</surname><given-names>R</given-names></name><name><surname>Miglietta</surname><given-names>AM</given-names></name><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Belfiore</surname><given-names>A</given-names></name><name><surname>Sims</surname><given-names>AH</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs)</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>39</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-020-01667-y</pub-id><pub-id pub-id-type="pmid">32778144</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Bae</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Bae</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide</article-title><source>Journal for Immunotherapy of Cancer</source><volume>7</volume><elocation-id>147</elocation-id><pub-id pub-id-type="doi">10.1186/s40425-019-0610-4</pub-id><pub-id pub-id-type="pmid">31174610</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Joo</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>SCC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NF-κB signaling in inflammation</article-title><source>Signal Transduction and Targeted Therapy</source><volume>2</volume><elocation-id>17023</elocation-id><pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id><pub-id pub-id-type="pmid">29158945</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Londoño-Vallejo</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Telomere length heterogeneity and chromosome instability</article-title><source>Cancer Letters</source><volume>212</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.05.008</pub-id><pub-id pub-id-type="pmid">15341022</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Doriga</surname><given-names>A</given-names></name><name><surname>Valle</surname><given-names>L</given-names></name><name><surname>Alonso</surname><given-names>MH</given-names></name><name><surname>Aussó</surname><given-names>S</given-names></name><name><surname>Closa</surname><given-names>A</given-names></name><name><surname>Sanjuan</surname><given-names>X</given-names></name><name><surname>Barquero</surname><given-names>D</given-names></name><name><surname>Rodríguez-Moranta</surname><given-names>F</given-names></name><name><surname>Sanz-Pamplona</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Telomere length alterations in microsatellite stable colorectal cancer and association with the immune response</article-title><source>Biochimica et Biophysica Acta. Molecular Basis of Disease</source><volume>1864</volume><fpage>2992</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2018.06.010</pub-id><pub-id pub-id-type="pmid">29908233</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Differential analysis of count data-the deseq2 package</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciejowski</surname><given-names>J</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Telomeres in cancer: Tumour suppression and genome instability</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.171</pub-id><pub-id pub-id-type="pmid">28096526</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>33</volume><fpage>1478</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.113.300168</pub-id><pub-id pub-id-type="pmid">23766387</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Barajon</surname><given-names>I</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IL-1 and IL-1 regulatory pathways in cancer progression and therapy</article-title><source>Immunological Reviews</source><volume>281</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1111/IMR.12614</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Molgora</surname><given-names>M</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interleukin-1 and Related cytokines in the regulation of inflammation and immunity</article-title><source>Immunity</source><volume>50</volume><fpage>778</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.012</pub-id><pub-id pub-id-type="pmid">30995499</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>P</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins</article-title><source>Nature Reviews. Cancer</source><volume>11</volume><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nrc3025</pub-id><pub-id pub-id-type="pmid">21346783</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname><given-names>EJ</given-names></name><name><surname>Luncsford</surname><given-names>PJ</given-names></name><name><surname>Armanios</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Long telomeres and cancer risk: The price of cellular immortality</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>3474</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1172/JCI120851</pub-id><pub-id pub-id-type="pmid">31380804</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medrek</surname><given-names>C</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name><name><surname>Jirström</surname><given-names>K</given-names></name><name><surname>Leandersson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients</article-title><source>BMC Cancer</source><volume>12</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-306</pub-id><pub-id pub-id-type="pmid">22824040</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hussain</surname><given-names>T</given-names></name><name><surname>Srivastava</surname><given-names>V</given-names></name><name><surname>Roy</surname><given-names>SD</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Telomere length-dependent transcription and epigenetic modifications in promoters remote from telomere ends</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007782</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007782</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Bagri</surname><given-names>S</given-names></name><name><surname>Kutum</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Kar</surname><given-names>A</given-names></name><name><surname>Dash</surname><given-names>D</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Telomere repeat-binding factor 2 binds extensively to extra-telomeric G-quadruplexes and regulates the epigenetic status of several gene promoters</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>17709</fpage><lpage>17722</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008687</pub-id><pub-id pub-id-type="pmid">31575660</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Non-duplex G-quadruplex structures emerge as mediators of epigenetic modifications</article-title><source>Trends in Genetics</source><volume>35</volume><fpage>129</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2018.11.001</pub-id><pub-id pub-id-type="pmid">30527765</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>NJ</given-names></name><name><surname>Dhillon</surname><given-names>VS</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Fenech</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A quantitative real-time pcr method for absolute telomere length</article-title><source>BioTechniques</source><volume>44</volume><fpage>807</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.2144/000112761</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oner</surname><given-names>G</given-names></name><name><surname>Altintas</surname><given-names>S</given-names></name><name><surname>Canturk</surname><given-names>Z</given-names></name><name><surname>Tjalma</surname><given-names>W</given-names></name><name><surname>Verhoeven</surname><given-names>Y</given-names></name><name><surname>Van Berckelaer</surname><given-names>C</given-names></name><name><surname>Berneman</surname><given-names>Z</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Pauwels</surname><given-names>P</given-names></name><name><surname>van Dam</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Triple-negative breast cancer-role of immunology: A systemic review</article-title><source>The Breast Journal</source><volume>26</volume><fpage>995</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1111/tbj.13696</pub-id><pub-id pub-id-type="pmid">31797488</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paeschke</surname><given-names>K</given-names></name><name><surname>McDonald</surname><given-names>KR</given-names></name><name><surname>Zakian</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Telomeres: Structures in need of unwinding</article-title><source>FEBS Letters</source><volume>584</volume><fpage>3760</fpage><lpage>3772</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2010.07.007</pub-id><pub-id pub-id-type="pmid">20637196</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>Goldeck</surname><given-names>D</given-names></name><name><surname>Derhovanessian</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inflammation, ageing and chronic disease</article-title><source>Current Opinion in Immunology</source><volume>29</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2014.03.007</pub-id><pub-id pub-id-type="pmid">24762450</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedram</surname><given-names>M</given-names></name><name><surname>Sprung</surname><given-names>CN</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Lo</surname><given-names>AWI</given-names></name><name><surname>Reynolds</surname><given-names>GE</given-names></name><name><surname>Murnane</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Telomere position effect and silencing of transgenes near telomeres in the mouse</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>1865</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.5.1865-1878.2006</pub-id><pub-id pub-id-type="pmid">16479005</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellatt</surname><given-names>AJ</given-names></name><name><surname>Wolff</surname><given-names>RK</given-names></name><name><surname>Torres-Mejia</surname><given-names>G</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Herrick</surname><given-names>JS</given-names></name><name><surname>Lundgreen</surname><given-names>A</given-names></name><name><surname>Baumgartner</surname><given-names>KB</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><name><surname>Hines</surname><given-names>LM</given-names></name><name><surname>Fejerman</surname><given-names>L</given-names></name><name><surname>Cawthon</surname><given-names>R</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Telomere length, telomere-related genes, and breast cancer risk: The breast cancer health disparities study</article-title><source>Genes, Chromosomes &amp; Cancer</source><volume>52</volume><fpage>595</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1002/gcc.22056</pub-id><pub-id pub-id-type="pmid">23629941</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Migliorini</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Clinical relevance of tumour-associated macrophages</article-title><source>Nature Reviews. Clinical Oncology</source><volume>19</volume><fpage>402</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00620-6</pub-id><pub-id pub-id-type="pmid">35354979</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: A flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raine</surname><given-names>KM</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Tarpey</surname><given-names>P</given-names></name><name><surname>Nik‐Zainal</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ascatNgs: Identifying somatically acquired copy‐number alterations from whole‐genome sequencing data</article-title><source>Current Protocols in Bioinformatics</source><volume>56</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1002/cpbi.17</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramadan</surname><given-names>WS</given-names></name><name><surname>Talaat</surname><given-names>IM</given-names></name><name><surname>Hachim</surname><given-names>MY</given-names></name><name><surname>Lischka</surname><given-names>A</given-names></name><name><surname>Gemoll</surname><given-names>T</given-names></name><name><surname>El-Awady</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of CBP expression in estrogen receptor-positive breast cancer</article-title><source>Clinical Epigenetics</source><volume>13</volume><elocation-id>72</elocation-id><pub-id pub-id-type="doi">10.1186/s13148-021-01060-2</pub-id><pub-id pub-id-type="pmid">33827682</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>TP</given-names></name><name><surname>Rosato</surname><given-names>RR</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Moulder</surname><given-names>S</given-names></name><name><surname>Piwnica-Worms</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A comprehensive overview of metaplastic breast cancer: Clinical features and molecular aberrations</article-title><source>Breast Cancer Research : BCR</source><volume>22</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/S13058-020-01353-Z/TABLES/2</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer</article-title><source>BMC Cancer</source><volume>20</volume><elocation-id>1076</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-020-07573-y</pub-id><pub-id pub-id-type="pmid">33167919</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>A</given-names></name><name><surname>Iachettini</surname><given-names>S</given-names></name><name><surname>Salvati</surname><given-names>E</given-names></name><name><surname>Zizza</surname><given-names>P</given-names></name><name><surname>Maresca</surname><given-names>C</given-names></name><name><surname>D’Angelo</surname><given-names>C</given-names></name><name><surname>Benarroch-Popivker</surname><given-names>D</given-names></name><name><surname>Capolupo</surname><given-names>A</given-names></name><name><surname>del Gaudio</surname><given-names>F</given-names></name><name><surname>Cosconati</surname><given-names>S</given-names></name><name><surname>Di Maro</surname><given-names>S</given-names></name><name><surname>Merlino</surname><given-names>F</given-names></name><name><surname>Novellino</surname><given-names>E</given-names></name><name><surname>Amoreo</surname><given-names>CA</given-names></name><name><surname>Mottolese</surname><given-names>M</given-names></name><name><surname>Sperduti</surname><given-names>I</given-names></name><name><surname>Gilson</surname><given-names>E</given-names></name><name><surname>Biroccio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>1820</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1202</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>JD</given-names></name><name><surname>Ludlow</surname><given-names>AT</given-names></name><name><surname>Batten</surname><given-names>K</given-names></name><name><surname>Magdinier</surname><given-names>F</given-names></name><name><surname>Stadler</surname><given-names>G</given-names></name><name><surname>Wagner</surname><given-names>KR</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Telomere position effect: Regulation of gene expression with progressive telomere shortening over long distances</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>2464</fpage><lpage>2476</lpage><pub-id pub-id-type="doi">10.1101/gad.251041.114</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>JD</given-names></name><name><surname>Ludlow</surname><given-names>AT</given-names></name><name><surname>Batten</surname><given-names>K</given-names></name><name><surname>Gaillard</surname><given-names>M-C</given-names></name><name><surname>Stadler</surname><given-names>G</given-names></name><name><surname>Magdinier</surname><given-names>F</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy</article-title><source>Genome Research</source><volume>25</volume><fpage>1781</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1101/gr.190660.115</pub-id><pub-id pub-id-type="pmid">26359233</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TL</given-names></name><name><surname>Holen</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tumour macrophages as potential targets of bisphosphonates</article-title><source>Journal of Translational Medicine</source><volume>9</volume><elocation-id>177</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-9-177</pub-id><pub-id pub-id-type="pmid">22005011</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>SY</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Histone acetyltransferases</article-title><source>Annual Review of Biochemistry</source><volume>70</volume><fpage>81</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.70.1.81</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname><given-names>R</given-names></name><name><surname>Gevaert</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Quantity of immune cells predict response to immunotherapy in cancer</article-title><source>EClinicalMedicine</source><volume>41</volume><elocation-id>101170</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101170</pub-id><pub-id pub-id-type="pmid">34746724</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansoni</surname><given-names>P</given-names></name><name><surname>Vescovini</surname><given-names>R</given-names></name><name><surname>Fagnoni</surname><given-names>F</given-names></name><name><surname>Biasini</surname><given-names>C</given-names></name><name><surname>Zanni</surname><given-names>F</given-names></name><name><surname>Zanlari</surname><given-names>L</given-names></name><name><surname>Telera</surname><given-names>A</given-names></name><name><surname>Lucchini</surname><given-names>G</given-names></name><name><surname>Passeri</surname><given-names>G</given-names></name><name><surname>Monti</surname><given-names>D</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><name><surname>Passeri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The immune system in extreme longevity</article-title><source>Experimental Gerontology</source><volume>43</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2007.06.008</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>AK</given-names></name><name><surname>Roy</surname><given-names>SS</given-names></name><name><surname>Bagri</surname><given-names>S</given-names></name><name><surname>Lier</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>M</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Nesse</surname><given-names>G</given-names></name><name><surname>Pandey</surname><given-names>DP</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human telomerase is directly regulated by non-telomeric TRF2-G-quadruplex interaction</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109154</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109154</pub-id><pub-id pub-id-type="pmid">34010660</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Hayflick, his limit, and cellular ageing</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>1</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/35036093</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of telomeres and telomerase in aging and cancer</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0062</pub-id><pub-id pub-id-type="pmid">27029895</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Terry</surname><given-names>MB</given-names></name><name><surname>Gurvich</surname><given-names>I</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Senie</surname><given-names>RT</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Short telomere length and breast cancer risk: A study in sister sets</article-title><source>Cancer Research</source><volume>67</volume><fpage>5538</fpage><lpage>5544</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3490</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonet</surname><given-names>T</given-names></name><name><surname>Zaragosi</surname><given-names>LE</given-names></name><name><surname>Philippe</surname><given-names>C</given-names></name><name><surname>Lebrigand</surname><given-names>K</given-names></name><name><surname>Schouteden</surname><given-names>C</given-names></name><name><surname>Augereau</surname><given-names>A</given-names></name><name><surname>Bauwens</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Santagostino</surname><given-names>M</given-names></name><name><surname>Giulotto</surname><given-names>E</given-names></name><name><surname>Magdinier</surname><given-names>F</given-names></name><name><surname>Horard</surname><given-names>B</given-names></name><name><surname>Barbry</surname><given-names>P</given-names></name><name><surname>Waldmann</surname><given-names>R</given-names></name><name><surname>Gilson</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The human TTAGGG repeat factors 1 and 2 bind to a subset of interstitial telomeric sequences and satellite repeats</article-title><source>Cell Research</source><volume>21</volume><fpage>1028</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1038/cr.2011.40</pub-id><pub-id pub-id-type="pmid">21423270</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>H</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Luesch</surname><given-names>H</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>ET</given-names></name><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Orth</surname><given-names>A</given-names></name><name><surname>de Jesus</surname><given-names>P</given-names></name><name><surname>Perry</surname><given-names>AS</given-names></name><name><surname>Oliver</surname><given-names>JD</given-names></name><name><surname>Tran</surname><given-names>NL</given-names></name><name><surname>Speiser</surname><given-names>LJ</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Saez</surname><given-names>E</given-names></name><name><surname>Schultz</surname><given-names>P</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name><name><surname>Tergaonkar</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression</article-title><source>Nature Cell Biology</source><volume>12</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/ncb2080</pub-id><pub-id pub-id-type="pmid">20622870</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unver</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>50</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2019.05.010</pub-id><pub-id pub-id-type="pmid">31151747</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinayagamurthy</surname><given-names>S</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Extra-telomeric impact of telomeres: Emerging molecular connections in pluripotency or stemness</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>10245</fpage><lpage>10254</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV119.009710</pub-id><pub-id pub-id-type="pmid">32444498</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinayagamurthy</surname><given-names>S</given-names></name><name><surname>Bagri</surname><given-names>S</given-names></name><name><surname>Mergny</surname><given-names>JL</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Telomeres expand sphere of influence: emerging molecular impact of telomeres in non-telomeric functions</article-title><source>Trends in Genetics</source><volume>39</volume><fpage>59</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2022.10.002</pub-id><pub-id pub-id-type="pmid">36404192</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Lian</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Role of tumor microenvironment in tumorigenesis</article-title><source>Journal of Cancer</source><volume>8</volume><fpage>761</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.7150/jca.17648</pub-id><pub-id pub-id-type="pmid">28382138</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The prognostic and clinical value of tumor-associated macrophages in patients with breast cancer: A systematic review and meta-analysis</article-title><source>Frontiers in Oncology</source><volume>12</volume><elocation-id>905846</elocation-id><pub-id pub-id-type="doi">10.3389/FONC.2022.905846/BIBTEX</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Wasiliew</surname><given-names>P</given-names></name><name><surname>Kracht</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interleukin-1 (IL-1) pathway</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>cm1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.3105cm1</pub-id><pub-id pub-id-type="pmid">20086235</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Telomeres and immune competency</article-title><source>Current Opinion in Immunology</source><volume>24</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.05.001</pub-id><pub-id pub-id-type="pmid">22626625</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Went</surname><given-names>PTH</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Meier</surname><given-names>S</given-names></name><name><surname>Bundi</surname><given-names>M</given-names></name><name><surname>Mirlacher</surname><given-names>M</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Dirnhofer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Frequent EpCam protein expression in human carcinomas</article-title><source>Human Pathology</source><volume>35</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2003.08.026</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentzensen</surname><given-names>IM</given-names></name><name><surname>Mirabello</surname><given-names>L</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The association of telomere length and cancer: A meta-analysis</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>20</volume><fpage>1238</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-11-0005</pub-id><pub-id pub-id-type="pmid">21467229</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willeit</surname><given-names>P</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Mayr</surname><given-names>A</given-names></name><name><surname>Weger</surname><given-names>S</given-names></name><name><surname>Oberhollenzer</surname><given-names>F</given-names></name><name><surname>Brandstätter</surname><given-names>A</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Telomere length and risk of incident cancer and cancer mortality</article-title><source>JAMA</source><volume>304</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.897</pub-id><pub-id pub-id-type="pmid">20606151</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Brasiskyte</surname><given-names>D</given-names></name><name><surname>Piatyszek</surname><given-names>MA</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids</article-title><source>The EMBO Journal</source><volume>15</volume><fpage>1734</fpage><lpage>1741</lpage><pub-id pub-id-type="pmid">8612598</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Songyang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human telomeric proteins occupy selective interstitial sites</article-title><source>Cell Research</source><volume>21</volume><fpage>1013</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1038/cr.2011.39</pub-id><pub-id pub-id-type="pmid">21423278</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Renault</surname><given-names>VM</given-names></name><name><surname>Jamet</surname><given-names>K</given-names></name><name><surname>Gilson</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Transcriptional outcome of telomere signalling</article-title><source>Nature Reviews. Genetics</source><volume>15</volume><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/nrg3743</pub-id><pub-id pub-id-type="pmid">24913665</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Z-Y</given-names></name><name><surname>Luo</surname><given-names>R-Z</given-names></name><name><surname>Peng</surname><given-names>R-J</given-names></name><name><surname>Wang</surname><given-names>S-S</given-names></name><name><surname>Xue</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis</article-title><source>OncoTargets and Therapy</source><volume>7</volume><fpage>1475</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.2147/OTT.S61838</pub-id><pub-id pub-id-type="pmid">25187727</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer</article-title><source>Journal for Immunotherapy of Cancer</source><volume>10</volume><elocation-id>e004047</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2021-004047</pub-id><pub-id pub-id-type="pmid">35110359</pub-id></element-citation></ref></ref-list></back><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95106.3.sa0</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This study highlights the role of role of telomeres in modulating IL-1 signaling and tumor immunity. The authors demonstrate a strong correlation between telomere length and IL-1 signaling by analyzing TNBC patient samples and tumor-derived organoids. Mechanistic insights revealed that non-telomeric TRF2 binding at the IL-1R1. The observed effects on NF-kB signaling and subsequent alterations in cytokine expression contribute significantly to our understanding of the complex interplay between telomeres and the tumor microenvironment. Furthermore, the study reports that the length of telomeres and IL-1R1 expression is associated with TAM enrichment. However, the manuscript lacks in-depth mechanistic insights into how telomere length affects IL-1R1 expression Overall, this work broadens our understanding of telomere biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95106.3.sa1</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, entitled &quot;Telomere length sensitive regulation of Interleukin Receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment&quot;, Dr Mukherjee and colleagues pointed at clarifying the extra-telomeric role of TRF2 in regulating IL1R1 expression with consequent impact on TAMs tumor-infiltration.</p><p>Strengths:</p><p>Upon a careful manuscript evaluation, I feel to conclude that the presented story is undoubtedly well conceived. At technical level, experiments have been properly performed and the obtained results well-support author conclusions.</p><p>Weaknesses:</p><p>Unfortunately, the covered topic is not particularly novel. In detail, TRF2 capability of binding extratelomeric foci in cells with short telomeres has been well demonstrated in a previous work published by the same research group. The capability of TRF2 to regulate gene expression is well-known, the capability of TRF2 to interact with p300 has been already demonstrated and, finally, the capability of TRF2 to regulate TAMs infiltration (that is the effective novelty of the manuscript) appears as an obvious consequence of IL1R1 modulation (this is probably due to the current manuscript organization).</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95106.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mukherjee</surname><given-names>Ananda Kishore</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Dutta</surname><given-names>Subhajit</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ankita</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shalu</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Shuvra Shekhar</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Antara</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Chatterjee</surname><given-names>Megha</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Vinayagamurthy</surname><given-names>Soujanya</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Bagri</surname><given-names>Sulochana</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Khanna</surname><given-names>Divya</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>Meenakshi</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Soni</surname><given-names>Dristhi</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Budharaja</surname><given-names>Anshul</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Technology Delhi</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Bhisade</surname><given-names>Sagar Kailasrao</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Science Education and Research, Bhopal</institution><addr-line><named-content content-type="city">Bhopal</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Anand</surname><given-names>Vivek</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Perwez</surname><given-names>Ahmad</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Nija</given-names></name><role specific-use="author">Author</role><aff><institution>National Centre for Biological Sciences</institution><addr-line><named-content content-type="city">Bangaluru</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Faruq</surname><given-names>Mohammed</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Ishaan</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Technology Delhi</institution><addr-line><named-content content-type="city">Delhi</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Radhakrishnan</surname><given-names>Sabarinathan</given-names></name><role specific-use="author">Author</role><aff><institution>National Centre for Biological Sciences</institution><addr-line><named-content content-type="city">Bangalore</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Chowdhury</surname><given-names>Shantanu</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Genomics and Integrative Biology</institution><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This manuscript from Mukherjee et al examines potential connections between telomere length and tumor immune responses. This examination is based on the premise that telomeres and tumor immunity have each been shown to play separate, but important, roles in cancer progression and prognosis as well as prior correlative findings between telomere length and immunity. In keeping with a potential connection between telomere length and tumor immunity, the authors find that long telomere length is associated with reduced expression of the cytokine receptor IL1R1. Long telomere length is also associated with reduced TRF2 occupancy at the putative IL1R1 promoter. These observations lead the authors towards a model in which reduced telomere occupancy of TRF2 - due to telomere shortening - promotes IL1R1 transcription via recruitment of the p300 histone acetyltransferase. This model is based on earlier studies from this group (i.e. Mukherjee et al., 2019) which first proposed that telomere length can influence gene expression by enabling TRF2 binding and gene transactivation at telomere-distal sites. Further mechanistic work suggests that G-quadruplexes are important for TRF2 binding to IL1R1 promoter and that TRF2 acetylation is necessary for p300 recruitment. Complementary studies in human triple-negative breast cancer cells add potential clinical relevance but do not possess a direct connection to the proposed model. Overall, the article presents several interesting observations, but disconnection across central elements of the model and the marginal degree of the data leave open significant uncertainty regarding the conclusions.</p><p>Strengths:</p><p>Many of the key results are examined across multiple cell models.</p><p>The authors propose a highly innovative model to explain their results.</p><p>Weaknesses:</p><p>Although the authors attempt to replicate most key results across multiple models, the results are often marginal or appear to lack statistical significance. For example, the reduction in IL1R1 protein levels observed in HT1080 cells that possess long telomeres relative to HT1080 short telomere cells appears to be modest (Supplementary Figure 1I). Associated changes in IL1R1 mRNA levels are similarly modest.</p><p>Related to the point above, a lack of strong functional studies leaves an open question as to whether observed changes in IL1R1 expression across telomere short/long cancer cells are biologically meaningful.</p><p>Statistical significance is described sporadically throughout the paper. Most major trends hold, but the statistical significance of the results is often unclear. For example, Figure 1A uses a statistical test to show statistically significant increases in TRF2 occupancy at the IL1R1 promoter in short telomere HT1080 relative to long telomere HT1080. However, similar experiments (i.e. Figure 2B, Figure 4A - D) lack statistical tests.</p></disp-quote><p>TRF2 overexpression resulted in ~ 5-fold or more change in <italic>IL1R1</italic> expression. Compared to this, telomere length-dependent alterations in <italic>IL1R1</italic> expression, although about 2-fold, appear modest (~ 50% reduction in cells with long telomeres across different model systems used). Notably, this was consistent and significant across cell-based model systems and xenograft tumors (see Figure 1). Unlike TRF2 induction, telomere elongation or shortening vary within the permissible physiological limits of cells. This is likely to result in the observed variation in <italic>IL1R1</italic> levels.</p><p>For biological relevance, we have shown this using multiple models where telomere length was either different (patient tissue, organoids) or were altered (cell lines, xenograft models) . Where IL1 signalling in TNBC tissue and tumor organoids, and cells/xenografts were shown to impact M2 macrophage infiltration in a telomere length sensitive fashion. We made use of the tumor organoids to test M2 macrophage infiltration using IL1RA and small molecule based <italic>IL1R1</italic> inhibition.</p><p>We have now included statistical tests in all the relevant figures and incorporated the necessary details about the tests performed in the figure legend for clarity of readers. Additionally, all data points, p values and details of statistical tests have been included in Figure wise excel sheets for both main and supplementary figures.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>There are typos throughout the manuscript. The word 'expression' is incorrectly spelled on y-axis labels throughout the manuscript (for example see Figure 1B). The word 'telomere' is incorrectly spelled in Supplementary Figure 1 legend panel A. Most errors, such as these, do not interfere with my comprehension of the manuscript. However, others made the manuscript difficult to follow. For example, I think that MDAMB231, MDAMD231, and MDAM231 are frequently used interchangeably to refer to the same cell line. This makes it very difficult to understand certain experiments.</p><p>I often found it difficult to understand which statistical test was used for a specific experiment. I suggest changing the style in the legends to more clearly connect statistical tests with specific data points.</p></disp-quote><p>We thank the reviewer for pointing out the typological errors. We have now made relevant corrections to both figures and text.</p><p>As stated above, we have now provided details of statistical tests performed in the figure legend for clarity of readers. Additionally, all data points, p values and details of statistical tests have been included in Figure wise excel sheets for both main and supplementary figures.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>This study highlights the role of telomeres in modulating IL-1 signaling and tumor immunity. The authors demonstrate a strong correlation between telomere length and IL-1 signaling by analyzing TNBC patient samples and tumor-derived organoids. Mechanistic insights revealed non-telomeric TRF2 binding at the IL-1R1. The observed effects on NF-kB signaling and subsequent alterations in cytokine expression contribute significantly to our understanding of the complex interplay between telomeres and the tumor microenvironment. Furthermore, the study reports that the length of telomeres and IL-1R1 expression is associated with TAM enrichment. However, the manuscript lacks in-depth mechanistic insights into how telomere length affects IL-1R1 expression. Overall, this work broadens our understanding of telomere biology.</p></disp-quote><p>The mechanism of how telomere length affects IL1R1 expression involves sequestration and reallocation of TRF2 between telomeres and gene promoters (in this case, the IL1R1 promoter). We have previously shown this across multiple genomic sites (Mukherjee et al, 2018; reviewed in J. Biol. Chem. 2020, Trends in Genetics 2023). We have described this in the manuscript along with references citing the previous works. A scheme explaining the model was provided as Additional Supplementary Figure 1, along with a description of the mechanistic model.</p><p>Figure 1-4 in main figures describe the molecular mechanism of telomere-dependent IL1R1 activation. This includes ChIP data for TRF2 on the IL1R1 promoter in long/short telomeres, as well as TRF2-mediated histone/p300 recruitment and IL1R1 gene expression. We further show how specific acetylation on TRF2 is crucial for TRF2-mediated IL1R1 regulation (Figure 5).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The study primarily provides a snapshot of cytokine expression and telomere length at a single time point. Longitudinal studies or dynamic analyses could provide a more comprehensive understanding of the temporal relationship between telomere length and cytokine expression.</p><p>Tumor heterogeneity is a significant problem for the various therapies. The study notes significant heterogeneity in telomere length but does not investigate the implications of this heterogeneity. Understanding the role of telomere length variation in different tumor cell populations is essential for a comprehensive interpretation of the results.</p><p>The study only mentions a correlation between IL1R1 and relative telomere length but does not provide any potential clinical correlations with patient outcomes or survival. Addressing the clinical relevance of these molecular changes would improve the translational impact.</p></disp-quote><p>The importance of IL1R1 in prognostic and clinical outcomes of TNBC has been studied by multiple groups. The overall consensus is that higher IL1R1 leads to poor prognosis – aiding both cancer progression and metastasis. Using publicly available TCGA data, we found that IL1R1 high samples had significantly lower survival in breast cancer (BRCA) datasets. The results have now been included in the manuscript as Supplemnetray Figure 7G.</p><p>Addition in text:</p><p>“We, next, used publicly available TCGA gene expression data of breast cancer samples (BRCA) (<bold>Supplementary file 4</bold>) to assess the effect of <italic>IL1R1</italic> expression on cancer prognosis. We categorized samples based on <italic>IL1R1</italic> expression: <italic>IL1R1</italic> high (N=254) and <italic>IL1R1</italic> low samples (N = 709). It was seen that overall patient survival was significantly lower in <italic>IL1R1</italic> high samples (Log-rank p value -0.0149) (Supplementary Figure 7G). We also checked the frequency of occurrence of various breast cancer sub-types in <italic>IL1R1</italic> high and low samples (Supplementary Figure 7H). While invasive mixed mucinous carcinoma (the most abundant sub-type) was predominantly seen in <italic>IL1R1</italic> low samples, metaplastic breast cancer was only found within the <italic>IL1R1</italic> high samples. Interestingly, metaplastic breast cancer has been frequently found to be ‘triple negative’-i.e., ER-,PR- and HER2-. (Reddy et al., 2020).”</p><p>However, we could not access a TNBC (or any breast cancer dataset) that has been characterized for telomere length. Unfortunately, the clinical TNBC samples that we had access to did not have any paired short-term/long-term survival datasets. We could, in principle, use TERT/TERC expression as a proxy for telomere length; however, in our experiments, we found that telomerase activity did not positively correlate with telomere length as expected (Supplementary Figure 7C, Supplementary Figure 8D). Therefore, transcriptional signature (of telomere-associated genes) may not be a reliable indicator of telomere length.</p><disp-quote content-type="editor-comment"><p>The study lacks in-depth mechanistic insights into how telomere length affects IL1R1 expression and subsequently influences TAM infiltration. Further molecular studies or pathway analyses are necessary to elucidate the underlying mechanisms.</p></disp-quote><p>The mechanism involves sequestration and reallocation of TRF2 between telomeres and gene promoters (in this case, IL1R1 promoter). We have previously shown this across multiple genomic sites (Mukherjee et al, 2018). We have appropriately discussed this in the manuscript.</p><p>A schematic explaining the model has been provided as Additional Supplementary Figure 1.</p><p>We have provided ChIP data for TRF2 on IL1R1 promoter in long/short telomeres in the manuscript as well as histone/p300 ChIP and gene expression (Figure 1-4 in main figures exclusively deal with molecular mechanism of telomere dependent IL1R1 activation). We further go on to show how specific acetylation on TRF2 might be crucial for TRF2-mediated IL1R1 regulation (Figure 5). One of the key findings herein is the fact that TRF2 can directly regulate <italic>IL1R1</italic> expression through promoter occupancy- tested in telomere altered cell lines (HT1080, MDAMB231) and tumor xenografts (Figure 1 A, F, I- for TRF2 promoter occupancy).</p><p>Pathway analysis of HT1080 (short vs long telomere) transcriptome, shows that cytokine-cytokine receptor interaction is one of the key pathways in upregulated genes.</p><p>While we have focused on TRF2 mediated <italic>IL1R1</italic> regulation, it is quite possible that there are other telomere sensitive pathways/mechanisms by which <italic>IL1R1</italic> is regulated. This has been duly acknowledged in the discussion.</p><disp-quote content-type="editor-comment"><p>The manuscript title suggests modulation of immune signaling in the tumor microenvironment, yet the authors exclusively focus on CD206+ TAMs, limiting the scope. It is recommended to investigate other immune cell types for a more comprehensive understanding of changes in the immune tumor microenvironment.</p></disp-quote><p>As stated above, we approached the manuscript from the purview of TRF2-mediated IL1R1 regulation. In our assessment of TCGA data for breast cancer, we found that CD206 (MRC1) had the highest enrichment in <italic>IL1R1</italic> high samples among key TAM and TIL markers- now added as Figure 8A (Details in Supplementary file 5). It also had the highest correlation with <italic>IL1R1</italic> among the tested markers. Therefore, we proceeded to check CD206+ve TAMs.</p><p>Now the following section has been added to text:</p><p>“We further found that the total proportion of immune cells (% of CD45 +ve cells) did not vary significantly between short and long telomere TNBC samples (Supplementary Figure 8C). However, TNBC-ST samples had a higher percentage of myeloid cells (CD11B +ve) within the CD 45 +ve immune cell population. We checked in three TNBC-ST and TNBC-LT samples each and found that the percentage of M1 macrophages (CD86 high CD 206 low) in the myeloid population was lower than that of the M2 macrophages (CD 206 high CD 86 low) and unlike the latter, did not vary significantly between the TNBC-ST and TNBC-LT samples (Supplementary Figure 8C).”</p><p>Unfortunately, due to sample limitations we are unable to test this on a larger cohort of samples.</p><p>A single cell transcriptome experiment may have been a good way to have a more comprehensive immune profiling. However, with our TNBC samples, isolated nuclei for downstream processing had low viability as per 10X genomics specifications.</p><disp-quote content-type="editor-comment"><p>Does IL1R1 influence TAM recruitment or polarization within the tumor microenvironment? To assess the impact, the authors should use a marker indicative of M1-like macrophages, such as CD80 or CD86.</p></disp-quote><p>To address the issue of TAM recruitment vs polarization meaningfully we need to characterize tissue resident macrophages as well as macrophages in circulation. We did not have access to patient blood. A murine breast cancer in-vivo model might be a more appropriate model to test this, which would take considerable time for us to develop. It is something that we hope to address in a follow up study.</p><disp-quote content-type="editor-comment"><p>Did the authors analyze other breast cancer subtypes for telomere length?</p></disp-quote><p>Unfortunately, other breast cancer sub-types besides TNBC were not available to us for experimentation.</p><disp-quote content-type="editor-comment"><p>Figure legends are very briefly written and need to be elaborated. Scale bars are also missing in images.</p><p>Add a gating strategy for flow cytometry results in Figure 8A.</p></disp-quote><p>Figure legend have been expanded for clarity. More prominent scale bars have been added for better visibility and reference. A relevant gating strategy has been added as Supplementary figure 8B.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>In this manuscript, entitled &quot;Telomere length sensitive regulation of Interleukin Receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment&quot;, Dr. Mukherjee and colleagues pointed out clarifying the extra-telomeric role of TRF2 in regulating IL1R1 expression with consequent impact on TAMs tumor-infiltration.</p><p>Strengths:</p><p>Upon careful manuscript evaluation, I feel that the presented story is undoubtedly well conceived. At the technical level, experiments have been properly performed and the obtained results support the authors' conclusions.</p><p>Weaknesses:</p><p>Unfortunately, the covered topic is not particularly novel. In detail, the TRF2 capability of binding extratelomeric foci in cells with short telomeres has been well demonstrated in a previous work published by the same research group. The capability of TRF2 to regulate gene expression is well-known, the capability of TRF2 to interact with p300 has been already demonstrated and, finally, the capability of TRF2 to regulate TAMs infiltration (that is the effective novelty of the manuscript) appears as an obvious consequence of IL1R1 modulation (this is probably due to the current manuscript organization).</p></disp-quote><p>Here we studied the TRF2-IL1R1 regulatory axis (not reported earlier by us or others) as a case of the telomere sequestration model that we described earlier (Mukherjee et al., 2018; reviewed in J. Biol. Chem. 2020, Trends in Genetics 2023). This manuscript demonstrates the effect of the TRF2-IL1R1 regulation on telomere-sensitive tumor macrophage recruitment. To the best of our knowledge, no previous study connects telomeres of tumor cells mechanistically to the tumor immune microenvironment. Here we focused on the IL1R1 promoter and provided mechanistic evidence for acetylated-TRF2 engaging the HAT p300 for epigenetically altering the promoter. This mechanism of TRF2 mediated activation has not been previously reported. Further, the function of a specific post translational modification (acetylation of the lysine residue 293K) of TRF2 in IL1R1 regulation is described for the first time. Additional experiments showed that TRF2-acetylation mutants, when targeted to the IL1R1 promoter, significantly alter the transcriptional state of the IL1R1 promoter. To our knowledge, the function of any TRF2 residue in transcriptional activation had not been previously described. Taken together, these demonstrate novel insights into the mechanism of TRF2-mediated gene regulation, that is telomere-sensitive, and affects the tumor-immune microenvironment.</p><p>We considered the reviewer’s suggestion to reorganize the result section. Reorganizing the manuscript to describe the TAM-related results first would, in our opinion, limit focus of the new findings and discovery [and novelty of the mechanisms (as described in above response, and in response to other comments by reviewers)] of the non-telomeric TRF2-mediated <italic>IL1R1</italic> regulation. We have tried to bring out the novelty, implications and importance of the TAM-related observations in the discussion.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>Based on the comments reported above, I would encourage the author to modify the manuscript by reorganizing the text. I would suggest starting from the capability of TRF2 to modulate macrophages infiltration. Data relative to IL1R1 expression may be used to explain the mechanism through which TRF2 exerts its immune-modulatory role. This, in my view, would dramatically strengthen the presented story.</p><p>Concerning the text, &quot;results&quot; should be dramatically streamlined and background information should be just limited to the &quot;introduction&quot; section.</p></disp-quote><p>The manuscript should be carefully revisited at grammar level. A number of incomplete sentences and some typos are present within the text.</p><p>We thank the reviewer for the appreciation of our work for its technical strengths.</p><p>At the onset, we agree that we have explored the TRF2-IL1R1 regulatory axis. This underscores the significance of the telomere sequestration model that we had proposed earlier (Mukherjee et al., 2018). Herein, however, we significantly extend our previous work (which was more general and intended for putting forward the idea of telomere-dependent distal gene expression) by studying TRF2-mediated regulation of IL1 signalling (which was previously unreported). In addition, mechanistic details of how telomeres are connected to IL1 signaling through non-telomeric TRF2 are entirely new, not reported before by us or others.</p><p>We have removed some text descriptions from the result section to streamline the section.</p></body></sub-article><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95106.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Yunlu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Macau</institution><country>Macao</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This study presents an <bold>important</bold> finding on the role of telomeres in modulating interleukin-1 signaling and tumor immunity in TNBC. The evidence supporting these findings is <bold>solid</bold>, presented through comprehensive analyses including TNBC clinical samples, tumor-derived organoids, cancer cells, and xenografts. The work will be of broad interest to cell and medical biologists focusing on TNBC.</p></body></sub-article></article>